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Abstract 
 
This project aims to develop a greater understanding of how old drugs can be repurposed 
into new and exciting therapeutic areas. In particular, developing an understanding of the 
antibacterial mode of action exerted by modified benzodiazepines possessing unique 
fluoropyridines will be explored. 
 
The work described in this thesis was mainly focused on the synthesis of a library of 
substituted benzodiazepines containing the fluoropyridine moiety and the biological 
investigation of these compounds. We present an effective synthetic route to the core 
benzodiazepine framework which was later attached to fluoropyridines. The target 
benzodiazepines substituted by Cl, Br and F on the aryl rings were synthesized and 
isolated successfully. Except the N1 substituted benzodiazepine, other target compounds 
all show great activity to a host of bacteria. 
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1.0 Introduction 
 
1.1 General Introduction 
Drug repurposing is a relatively new approach to the drug development process that 
provides the quickest possible transition from bench to bedside. The purpose of this 
project is to understand how approved drugs can be repurposed safely and effectively 
into other therapeutic areas. Specifically, this work studies the antibacterial mode of 
action exerted by benzodiazepine derivatives containing the unique fluoropyridine 
moieties. This will be achieved by structure-activity-relationship studies around the core 
benzodiazepine framework (Figure 1). The report is composed of five chapters. The 
remainder of this chapter will provide a brief introduction to antibiotics, their mode of 
action and background to the project. Chapter two contains the results of the study and 
the associated discussion with Chapter three providing the biological investigation of the 
target compounds. The conclusion and further work of the research will be given in the 
Chapter four and the Chapter five will be experimental details. 
 
 
Figure 1: The structures of benzodiazepine derivatives. 
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1.2 Brief History of Antibiotics 
Antibiotics have enjoyed high reputation since they were introduced into the area of 
medicine in the 1940s. Their functions have extended from inhibiting or terminating the 
growth of bacteria to the prophylaxis of infectious diseases in patients and other living 
animals.1 The noun “antibiosis” was created by Vuillemin in 1889 to describe the 
antagonism effect among the living source world. But the term “antibiotic” could not be 
found in the literature during the several decades afterwards until it was defined and used 
by S. A. Waksman in 1942, referring specifically the antagonistic substances produced 
by micro-organisms.2 In the following years, the meaning of antibiotics had differed from 
chemotherapeutic drugs. Antibiotics were drugs taken from natural plants such as fungi 
and endophytic bacteria while chemotherapeutic drugs were artificially synthesised. 
However, the difference faded away when chemists successfully synthesized news drugs 
that acted as antibiotics.3 Nowadays, a large number of antibiotics made in the laboratory 
are available, known as synthetic antibiotics and semisynthetic antibiotics.4  
 
The investigation of intermicrobic antagonism is nearly as old as the science of 
microbiology.5 To set a well-known example, the father of microbiology L. Pasteur and 
his colleague Joubert described in 1877 that anthrax bacilli would die when the sample 
was contaminated by unspecified bacteria in the air.6,7 Therapeutic applications of the 
observation rapidly followed.  
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After this, early application of chemotherapeutic agents, like mercury and the arsenical 
derivatives, were employed. This was based on a poison principle, meaning the content 
of their poison was controlled by pharmacists to make sure that they were not too toxic, 
but could kill the bacterial infection.8 R. Dubos from the Rockefeller Institute was the 
first researcher to have a different opinion of how antibacterial agents should work. He 
was trying to find a purifying substance from the environment of the edaphic bacterium 
Stretococcus pneumoniae because he believed that there must be such a component 
antagonistic to the spread of Stretococcus pneumoniae to keep the ecological balance in 
the soil.4 His finding, tyrothricin, isolated from the soil bacterium Bacillus brevis showed 
antimicrobial activity against the growth of Stretococcus pneumoniae, but unfortunately 
this product was not pure. The active ingredient of the impurities was later proved to be 
gramicidin by his colleague R. Hotchkiss and other scientists. Although gramicidin is not 
as toxic as mercury and arsenic, it is still not suitable to be used inside of human bodies.2,5 
 
Whilst an effective approach, future research focused on the discovery of new 
antibacterials through application of other chemical entities.  
 
 
 
 
 
4 
 
1.2.1 Sulphonamides 
When Dubos was looking for the purifying substances from the natural products, another 
research line of antibacterial agents developed compounds via chemical modification 
was also in progress by other scientists.  
In 1932, prontosil 4 was first prepared by Klarer and Meitzsch as a dye in Bayer 
laboratories. Three years later, Domagk noticed that prontosil molecules were able to 
slow down the extension of staphylococcal infections in human.5 Prontosil 4 was 
discovered to be a pro-drug as the active agent; sulphonamides 5 were the active 
components and human friendly agents (Figure 2).9  
 
 
Figure 2: The structures of prontosil 4 and its breakdown product 5. 
 
This successful discovery allowed scientists to think over the selective toxicity of 
antibiotics. The synthesis of the first sulphonamide drug, prontosil 4, was deemed to be 
the beginning of the antibiotics era. The boom of sulphonamides immediately followed 
— around 5000 developed sulfa drugs appeared in the 1930s and 1940s.10 The application 
of sulphonamides extended rapidly from treating staphylococcal infections to pneumonia, 
meningitis, etc. Especially, sulfa drugs made great contributions to the treatment of 
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puerperal pyrexia.11 Owing to the efforts of Colebrook and Kenny on developing sulfa 
drugs to prevent the puerperal fever which dropped the incidence of puerperal fever per 
100,000 population from 20 to around 10, the birth death rate in England and Wales 
declined sharply between 1935 and 1950.11 
 
 
1.2.2 Penicillin 
Another early antibiotic is penicillin 6, a more remarkable substance than sulphonamides, 
which was first prepared from Penicillium notatum by A. Fleming in 1929.10 This 
discovery was initially not valued by people, until 1940 when Fleming’s trials on 
penicillin 6 caught the attention of Professor Florey in the University of Oxford. With 
the help of E. Chain and other chemists, Florey successfully extracted and purified the 
active component ingredient on a mass scale (Figure 3).2,5   
 
 
Figure 3: The core structure of penicillin 6, where “R” is the variable group. 
 
In the early 1940s, resistance to sulphonamides began to occur. The purified penicillin 6 
was an important remedy for the bacterial infections which could not be treated by sulfa 
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drugs. The commercial production of penicillin 6 was achieved by Merck & Co in 
America.12 During World War I, without effective treatments, soldiers died due to not 
only the combat wounds but also blood poisoning. The large-scale production of 
penicillin 6 during the Second World War saved millions of people’s lives with the 
mortality from pneumonia in the American Army decreasing from approximate 18% in 
World War I to less than 1% in World War II.10 
 
 
1.2.3 Streptomycin 
Different from the early discoveries, streptomycin 7 was not discovered by accident. 
Focusing on a large group of bacteria known as actinomycetes, S. A. Waksman’s team 
carried out a rigorous and systematic investigation in which they looked at 10,000 
different soil microbes.13 In 1943, the PhD student A. Schatz in his lab found two strains 
of Streptomyces bacteria that produced a substance which could stop other bacteria 
growing.14 This new antibiotic was named streptomycin 7 and it was proved to be the 
first antibiotic that could kill Mycobacterium tuberculosis (Figure 4).15  
 
     
Figure 4: The structure of streptomycin 7 (left) and the scanning electron micrograph of Mycobacterium 
tuberculosis bacteria (right). 
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Furthermore, not only was streptomycin 7 found to be effective and safe in treating 
tuberculosis, eventually it was found to be active against 70 different types of bacteria 
which do not respond to penicillin 6 including infections of the abdomen, urinary tract, 
pelvis and meninges.16 Streptomycin 7 was an antibiotic that inhibited both gram-positive 
and gram-negative bacteria, and was therefore a very useful broad-spectrum antibiotic.17 
 
 
1.2.4 Tetracyclines 
S. Waksman’s work and methods on chemical diversity derived from soil actinomycetes 
was great evidence that the microbial world could produce a wealth of natural products 
and antibiotic compounds capable of fighting microbial diseases. Hence, many 
pharmaceutical companies expanded within the United States to commit to antibiotic 
research and development.18 Aureomycin (chlortetracycline) 8 produced by Cyanamid 
was extracted from the gold-coloured Streptomyces strain. It was first published in 1948 
in the Annals of the New York Academy of Sciences,19 described as a safe, effective and 
broad-spectrum antibacterial agent. With similar colour to aureomycin 8, terramycin 
(oxytetracycline) 9 was later obtained by Alexander Finlay and colleagues at Charles 
Pfizer Co., Inc. Their structures were published in 1954 by the Pfizer-Woodward group 
(Figure 5).18  
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Figure 5: The structures of first generation tetracyclines: aureomycin 8, terramycin 9 and teracyn 10. 
 
The core scaffold for this new family of antibiotics became descriptively known as the 
tetracyclines. Pfizer’s Lloyd Conover believed that chlorine in aureomycin 8 was not 
responsible for activity. Using palladium metal and hydrogen as catalysts, aureomycin 
was hydrogenated to synthesize teracyn 10 possessing higher potency, better solubility 
profile and favourable pharmacological activity.17 By the mid-1950s, these three 
tetracyclines 8, 9 and 10 were used clinically and saved tens of thousands of lives.20 
 
 
 
9 
 
Second generation semisynthetic analogs and more recently third generation compounds 
show the continued evolution of the tetracycline scaffold toward derivatives with 
increased potency as well as efficacy against tetracycline-resistant bacteria, with 
improved pharmacokinetic and chemical properties (Figure 6).20  
 
 
Figure 6: Selected members of second generation and third generation tetracyclines. 
 
Their biological activity against a wide spectrum of microbial pathogens and their uses 
in mammalian models of inflammation, neurodegeneration, and other biological systems 
indicate that the tetracyclines will continue to be successful therapeutics in infectious 
diseases and as potential therapeutics against inflammation-based mammalian cell 
diseases.21,22 
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1.2.5 Vancomycin 
In the early 1950s, the available antibiotics were failing to control staphylococcus 
infections in many hospitalized patients.23 A large-scale screening program was 
performed by Eli Lilly and Company in order to develop effective new agents against 
staphylococci. A soil sample found in the jungles of Borneo by a missionary friend of 
the organic chemist at Lilly contained a microorganism, Streptomyces orientalis which 
produced an active substance which was later called vancomycin 13 (Figure 7).24  
 
 
Figure 7: The structure of vancomycin 13. 
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Vancomycin 13 was shown to be highly bactericidal against all staphylococcal strains 
and was relatively safe when administered to patients. However, methicillin 14 and 
cephalothin 15 were already commercially available to treat severe staphylococcal 
infections, therefore interest in vancomycin 13 diminished after its introduction (Figure 
8).25  
 
 
Figure 8: The structures of methicillin 14 and cephalothin 15. 
 
Nevertheless, methicillin 14 was used widely and an increasing incidence of methicillin 
resistant strains of Staph. aureus and Staph. epidermidis was reported in the United States 
and Europe.26 Consequently, use of either methicillin 14 or cephalothin 15 was not 
recommended if a resistant strain was found in patients but vancomycin 13 was used as 
an alternative.25,26 This has seen a corresponding increase in the use of vancomycin 13 
since other antistaphylococcal antibiotics could not decrease the incidence of  
staphylococcal infections.26 Nowadays, vancomycin 13 is also used for prophylaxis in 
patients with reduced renal function undergoing dialysis and to eradicate staphylococci 
and clostridia which can cause severe antibiotic-induced enterocolitis. Combined with 
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other antimicrobial agents, oral vancomycin 13 is able to suppress the intestinal flora of 
the patients with cancer thereby prevent infection from their own commensal 
organisms.24 
 
 
1.2.6 Rifampicin and Related Rifamycins 
Rifampicin 21 has a high level of activity against mycobacteria, gram-positive and gram-
negative cocci, many gram-negative bacilli, most anaerobes, and cellular prokaryotic 
parasites (e.g. Chlamydia and Brucella).27 It was first developed in the Dow-Lepetit 
Research Laboratories in Milan, Italy as part of an extensive program of chemical 
modification of the rifamycins, the natural metabolites of Nocardia mediterranei.28 
Individual components of the rifamycin complex were designated as rifamycin A, B 16, 
C, D, and E according to their mobility on paper chromatography. But most of them were 
unstable; only rifamycin B 16 could be isolated in pure crystalline form. Rifamycin B 16 
was the least active component of the rifamycin complex but showed an extremely low 
level of toxicity and a moderate level of therapeutic activity in infections in animals. It 
was found that rifamycin B 16 could reversibly convert to rifamycin O 17 which was 
hydrolyzed to rifamycin S 18 in the process of losing one molecule of glycolic acid. By 
mild reduction of rifamycin S 18, rifamycin SV 19 was obtained (Figure 9).28,29  
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Figure 9: Structural formulas for rifampicin and some earlier rifamycins. 
 
Different from rifamycin B 16, rifamycin SV 19 is extremely active against gram-
positive bacteria including Mycobacterium tuberculosis, and moderately active against 
some gram-negative bacteria.30,31 Thus, it was introduced in some countries for the 
parenteral and topical treatment of infections due to gram-positive bacteria and infections 
of the biliary tract.  
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In the effort to obtain a new rifamycin with improved chemotherapeutic properties, such 
as better oral absorption, more prolonged antibacterial levels in blood, greater activity 
against mycobacterial infections and infections resulting from gram-negative bacteria, 
several hundred semisynthetic derivatives had been prepared. In various experimental 
results, the hydrazone of 3-formylrifamycin SV 20 with N-amino-N'-methylpiperazine 
designated rifampicin 21, also known as rifampin, that was the most active for oral 
administration and was also the least toxic.27 After successful clinical trials, rifampicin 
21 was introduced into therapeutic use in 1968. In the intervening years, a large number 
of clinical and biologic studies had confirmed the important role of rifampicin 21 in 
therapy for tuberculosis and other selected infectious diseases.32,33 
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1.3 Mechanisms of Antibiotic Action 
Although all antibiotics are able to inhibit or terminate the growth of bacterial infections, 
their operating principles cannot be described with a uniform pattern. Generally, 
antibiotics are classified into two categories, bactericidal and bacteriostatic. Bactericidal 
antibiotics kill the organism while bacteriostatic antibiotics only slow down the bacterial 
growth and reproduction.34,35 The mechanism of antibiotic action can be further 
subdivided into three main categories based on their microbial cell targets: cell wall 
synthesis, protein synthesis and nucleic acid synthesis (Figure 10).36,37  
 
 
Figure 10: Classification of antibiotics based on their mechanism of action. 
 
The following section will highlight how the antibiotics described in section 1.2 function 
to either kill the bacteria or act to slow the growth of a bacterial infection.  
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1.3.1 Cell Wall Synthesis 
The bacterial cell wall is the principal stress-bearing and shape-maintaining element in 
bacteria, and its integrity is of critical importance to cell viability.38 In both gram-positive 
and gram-negative bacteria, the scaffold of the cell wall consists of the cross-linked 
polymer pepticdoglycan which is the critical site attacked by anti-cell-wall agents. The 
peptidoglycan layer is essential for the survival of bacteria in hypotonic environments. 
Any loss or damage of this layer destroys the rigidity of the bacterial cell wall, resulting 
in death.38,39  
 
Peptidoglycan synthesis occurs in three stages. The final stage of the extracellular 
biosynthesis in two steps: in the transglycosylation step, the disaccharide phospholipid 
lipid II is polymerized to form polysaccharide strands, and in the subsequent 
transpeptidation step, these strands are cross-linked (Figure 11).40  
 
 
Figure 11. The final stage of the biosynthesis of peptidoglycan. 
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Penicillin 6，a β-lactam antibiotic, kills susceptible bacteria by specifically inhibiting the 
transpeptidase, a penicillin-binding protein (PBP), that catalyzes the cross-linking of 
peptidoglycan.41 Transpeptidase normally binds to the D-Ala-D-Ala 22 at the end of 
peptidoglycan precursors to crosslink the peptidoglycan. β-Lactams such as penicillin 6 
mimic D-Ala-D-Ala 22, occupying the PBP active site and inhibiting crosslinking of 
peptidoglycan peptide bridges cells (Figure 12). The cell wall is then weakened which 
allows autolytic enzymes that degrade the peptidoglycan network to dominate, leading 
to lysis of the cells.41,42 
 
  
Figure 12: β-Lactams such as penicillin 6 (black) have similar structures to D-Ala-D-Ala 22 (red).   
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In a different process, vancomycin 13 interrupts cell wall synthesis by forming a complex 
with the C-terminal D-alanine residues of peptidoglycan precursors (Figure 13).43  
 
 
Figure 13: D-Ala-D-Ala 22 (bacterial cell wall precursor, in blue) binds to vancomycin 13 (black) 
through hydrogen bonds. 
 
Complex formation at the outer surface of the cytoplasmic membrane prevents the 
transfer of the precursors from a lipid carrier to the growing peptidoglycan wall by 
transglycosidases.43 Biochemical reactions in the cell wall catalyzed by transpeptidases 
and D,D-carboxypeptidases are also inhibited by vancomycin 13 and other glycopeptide 
antimicrobials. Because of its large size and complex structure, vancomycin 13 does not 
penetrate the outer membrane of gram-negative organisms. With resistance to β-lactams 
increasing in frequency among staphylococci and enterococci, glycopeptides such as 
vancomycin 13 remain important therapeutic agents.39,44 
 
Vancomycin 13 
D-Ala-D-Ala 22 
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1.3.2 Nucleic Acid Synthesis 
Antimicrobial agents interfere with nucleic acid synthesis at several different levels. They 
can inhibit nucleotide synthesis or interconversion; they can prevent DNA from 
functioning as a proper template; and they can interfere with the polymerases involved 
in the replication and transcription of DNA.36 Rifamycins are a class of antibiotics that 
inhibit DNA-directed RNA polymerase. Polypeptide chains in RNA polymerase attach 
to σ factor that confers specificity for the recognition of promoter sites that initiate 
transcription of the DNA. Rifampicin 21, a semisynthetic derivative, binds non-
covalently but strongly to the β subunit of RNA polymerase and interferes specifically 
with the initiation process. However, it has no effect once polymerization has begun 
(Figure 14).39,44 
   
Figure 14: Rifampicin 21 (green) binds to RNA polymerase (blue) and changes its conformation so that it 
cannot initiate RNA synthesis. 
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Folate is a major carrier of one-carbon groups needed for methylation reactions and 
nucleotide synthesis, that is required for growth by both bacterial and mammalian cells.45 
Animals and man are unable to synthesize folate, so it must be supplied in the diet. Folate 
is accumulated by mammalian cells, but not by bacteria, which must synthesize the 
compound intracellularly. This difference between the biochemistry of bacterial and 
mammalian cells is the basis of the selective toxicity of sulphonamides, the first effective 
chemotherapeutic agents to be used systematically for the treatment of bacterial 
infections.45,46 
 
Sulphonamides 25 are structural analogues of para-aminobenzoic acid (PABA) 24. They 
act as alternative substrates for the key biosynthetic enzyme dihydropteroate synthetase 
(DHPS) which catalyses the formation of the folate intermediate dihydropteroic acid 26 
from PABA 24 and dihydroteroate diphosphate (pteridine) 23.47,48 Inhibition of 
dihydropteroate synthetase results from the formation of inactive folate-like analogues 
from sulphonamides 25 and dihydroteroate diphosphate 23. This blocks the further 
biosynthesises of dihydrofolic acid 27 as well as tetrahydrofolate 28 in bacterial cells 
which is an enzyme cofactor for the synthesis of the pyrimidine nucleic acid bases 
required for DNA synthesis both for bacteria and humans (Figure 15).  
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Figure 15: The mechanism of action of the sulphonamides 25. 
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1.3.3 Protein Synthesis 
Protein synthesis is a complex, multi-step process involving many enzymes as well as 
conformational alignment. However, the majority of antibiotics that block bacterial 
protein synthesis interfere with the processes at the 30S subunit or 50S subunit of the 
70S bacterial ribosome.49,50 The aminoacyl tRNA synthetases that activate each amino 
acid required for peptide synthesis are not antibiotic targets. Instead, there are three 
primary steps in the process that are attacked: (1) the formation of the 30S initiation 
complex which is made up of mRNA, the 30S ribosomal subunit and formyl-methionyl-
transfer RNA, (2) the formation of the 70S ribosome from the 30S initiation complex 
and the 50S ribosome, and (3) the elongation process of assembling amino acids into a 
polypeptide.50-52 
 
 
 
 
 
 
 
 
23 
 
Aminoglycoside antibiotics have an affinity for the 30S ribosome subunit and can bind 
irreversibly to it. Streptomycin 7 is one of the most commonly used aminoglycosides, 
disturbing several steps of protein synthesis leading to translational errors and slowdown 
of translocation.51 The firm binding of streptomycin 7 to the decoding centre on the 30S 
subunit of the ribosome induces related structural rearrangements that explain the 
observed effects on miscoding. This misreading of the codons causes an error in the 
proofreading process of translation leading to improper protein expression and 
ultimately resulting in bacterial cell death (Figure 16).53 
 
 
 
Figure 16: The binding of streptomycin 7 to the 30S subunit leads to the misreading of codon. In this 
example, the codon CGC codes for the amino acid arginine. However, the near-match tRNA carries the 
amino acid leucine not arginine by misreading. 
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As mentioned in the section 1.2.4, the tetracycline class of antibiotics is a large family of 
broad spectrum bacteriostatic agents that have a limited but very important role in the 
armamentarium of antibacterial agents.20,52 Tetracycline enters the cell by either passive 
diffusion or by energy dependent transport systems. Once inside the cell, they act by 
binding reversibly to the 30S ribosomal subunit at the A site. During protein biosynthesis, 
the new tRNA with the amino acid attempts to bind to A-site of the ribosome. However, 
the A-site is blocked by the tetracycline and the aminoacyl tRNA cannot bind to it. 
Without the sequential attachment of the tRNA at the A-site, protein biosynthesis is 
ultimately terminated leading to a bacteriostatic effect (Figure 17).51,52 
 
  
Figure 17: The primary target of tetracycline is the 30S subunit of the ribosome, preventing the binding 
of aminoacyl tRNA to the acceptor site on mRNA. 
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1.4 Antibiotic Resistance 
Despite the enormous success of antibiotics as chemotherapeutic agents, infectious 
diseases continue to be a leading cause of mortality worldwide. Bacteria have the 
capability to regenerate in approximately 30 minutes with a fresh possibility to mutate 
and adapt to a brand-new environment. 56 The widespread use of prescription antibiotics 
places a selective pressure on bacteria and favours the survival of the fittest and more 
adapted strains. As a result, increasing bacteria have developed resistance against 
antibacterial agents and the antibiotics can no longer bind to the bacterial receptor or 
enter the bacterial cell to harm bacterial propagation and reproduction.56,57 
 
Antimicrobial resistance readily occurring in a variety of bacterial genera due to the 
following important mechanisms. First, the organism may acquire genes encoding 
enzymes, such as β-lactamases, that destroy the antibacterial agent before it can have an 
effect. Second, bacteria may acquire efflux pumps that extrude the antibacterial agent 
from the cell before it can reach its target site and exert its effect. Third, bacteria may 
acquire several genes for a metabolic pathway which ultimately produces altered 
bacterial cell walls that no longer contain the binding site of the antimicrobial agent, or 
bacteria may acquire mutations that limit access of antimicrobial agents to the 
intracellular target site via downregulation of porin genes.56,58 Several case studies of 
antibiotic resistance are displayed in the following section.  
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1.4.1 Resistance to Sulphonamides 
Sulphonamides 25 were the first antimicrobials developed for large-scale introduction 
into clinical practice. But nowadays, they are infrequently used in part due to widespread 
resistance.59 Most bacteria are capable of developing resistance to sulphonamides such 
as Escherichia coli, Staphylococcus aureus, Pneumocystis carinii, Campylobacter jejuni, 
Streptococcus pyogenes, Mycobacterium leprae and Neisseria meningitidis.56 As 
mentioned in the section 1.3.2, the target of sulphonamides 25 and the basis for their 
selectivity is the enzyme dihydropteroate synthase (DHPS) in the folic acid pathway. 
Therefore, the bacterial resistance to sulphonamides 25 presumably originates by mutants 
that producing increased amounts of PABA 24, lowering affinity for sulphonamides 25 
or adopting an alternative pathway in folate metabolism.59 For instance, the dhps (folP) 
gene of two highly sulphonamide-resistant strains of S. pyogenes was found to be 
substantially altered. The resistant mutants having additional compensatory mutations in 
DHPS allow it to function normally.56 
 
Remarkably, sulphonamide resistance in gram-negative enteric bacteria is plasmid-borne 
and is effected by genes encoding alternative drug-resistance variants of the DHPS 
enzymes. Two plasmid-borne genes, sul1 and sul2, produce DHPSs distinct between 
themselves which showing pronounced insensitivity to sulphonamide inhibition in 
combination with normal substrate saturation. These enzymes seem to be able to 
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distinguish very sharply between PABA 24 and the structurally very similar 
sulphonamides 25.56,59  
 
 
1.4.2 Resistance to β-Lactams 
There are hundreds of β-lactamases that have been discovered and characterized since 
the first penicillin-resistant S. aureus identified in the mid-1940s expressed a β-lactamase 
that afforded resistance.59 Based on their structures, β-lactamases can be divided into four 
groups: the class A, C, D enzymes with a serine residue at their active sites and the class 
B proteins which are zinc-dependent metalloenzymes.60 Some class A proteins are 
extended-spectrum β-lactamases and function as carbapenemases. The class B 
metalloenzymes that hydrolyze carbapenems are susceptible to the inhibition by EDTA 
but not susceptible to the inhibition by clavulanate. The plasmid-borne ampC gene is the 
prototype class C enzyme which has been found in many species of the 
Enterobacteriaceae and P. aeruginosa. Besides, it was also reported to be transferred 
among E. coli, Klebsiella spp. and Salmonella spp.. Class D enzymes have been found 
in only a few species such as P. aeruginosa, Acinetobacter spp. and Aeromonas spp..59,60  
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To resist the effects of penicillin 6 and other β-lactam antibiotics, these β-lactamases 
break the bond in the β-lactam ring to inactivate the molecule before it reaches the cell 
membrane (Figure 18).61-63 
 
 
Figure 18: Mode of action of β-lactamase. 
 
Apart from β-lactamases, the β-lactam resistance is mediated by altered PBPs as which 
are present in almost all the bacteria but their number, size and affinity to β-lactam varies 
from species to species.54 For example, the resistance in the staphylococci and 
streptococci frequently occurs following the acquisition of genes for PBPs that are not 
sensitive to β-lactam inhibition.59 
 
 
1.4.3 Resistant to Aminoglycosides   
Resistance to aminoglycosides is widely reported, but the preponderance of the cases of 
resistance to these agents has not been as overwhelming as β-lactam resistance. This may 
be owing to the more frequent use of β-lactams in the clinic and the different mechanisms 
of dissemination of the resistance determinants.64 The most common mechanism for 
clinical resistance to aminoglycosides is their structural modification by specific 
enzymes expressed in the resistant organisms: aminoglycoside acetyltransferases 
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(AACs), aminoglycoside nucleotidyltransferases (ANTs) and aminoglycoside 
phosphotransferases (APHs).64,65 The acetyltransferases are capable of modifying 
tobramycin, gentamicin, netilmicin, and amikacin; the nucleotidyltransferase proteins 
alter the activity of tobramycin; and the phosphotransferases affect amikacin 
susceptibility.59 Streptomycin 7, the first drug to be discovered named aminoglycosides, 
is set as an example. The resistance to streptomycin 7 due to aminoglycoside 
phosphotransferases is the result of two classes of enzymes, the APH(3”)s and the 
APH(6)s, both of which are found in the streptomycin producer Streptomyces griseus. 
Catalyzed by either APH(3”)s or APH(6)s, the phosphoryl transfer is directed to the 3”- 
or 6-hydroxyl group of the aminocyclitol ring (Figure 19).65 
 
 
 
Figure 19: Reactions catalyzed by APH(3’’) and APH(6). The aminocyclitol rings are numbered simply 
and attached carbohydrates are designated with prime (’) or double prime (”) superscripts. ATP: adenosine 
triphosphate. 
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1.4.4 Resistance to Tetracyclines 
The most prevalent forms of resistance to the tetracyclines in the clinic are drug efflux 
and ribosome protection.59 Tetracycline efflux is achieved by the export protein, Tet, 
from the major facilitator superfamily (MFS). This export protein is shown to function 
as an electroneutral antiport system which catalyzes the exchange of the protons (H+) for 
the tetracyclines against a concentration gradient.18,59,66,67 In gram-negative bacteria, the 
export protein contains 12-TMS (transmembrane fragments) (e.g. TetA-E) whereas in 
gram-positive bacteria, it displays 14-TMS (e.g. TetK and TetL).59,66 Most tetracycline 
efflux pumps confer resistance to tetracycline 10, but are less effective against second 
generation doxycycline 11, and confer little or no resistance to third generation 
glycylcyclines, such as tigecycline 12 (Figure 20).67 
 
 
 
Figure 20: Schematic for mechanism of action of tetracycline efflux pump, Tet, illustrating that efflux of 
tetracycline 10 (but not tigecycline 12) is coupled to proton transport. 
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The second type of tetracycline resistance, a protein-based ribosomal protection 
mechanism, was first found in streptococci and later in anaerobic bacteria.18 When 
tetracyclines bind to ribosomes they normally stop elongation of synthesizing proteins. 
However, ribosomal protection proteins, such as TetM and TetO, interact with the 
ribosome causing the tetracycline to dislodge from the ribosome, thus protecting the 
bacterial cell from tetracyclines inhibitory activity, resulting in cellular growth.18,20,59,67 
 
More recently, a less prevalent resistance mechanism has been described, involving a 
cytoplasmic protein, TetX, that chemically modifies tetracyclines. This is shown to be 
due to an oxygen-dependent ﬂavin-monooxygenase enzyme encoded by the distinct gene 
tetX.59,66-68 Curiously, the reaction only takes place in the presence of oxygen and 
NADPH and does not function in the natural host, an anaerobe Bacteroides (Figure 
21).18,67,68 
 
 
 
Figure 21: TetX-madiated reaction of chlortetracycline 8 to hydroxy-chlortetracycline 32. NADPH: 
nicotinamide adenine dinucleotide phosphate reductase. 
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1.4.5 Resistance to Vancomycin 
Vancomycin 13 has been widely used in the treatment of serious infections with gram-
positive bacteria, and particularly it has been invaluable in the treatment of methicillin-
resistant Staphylococcus aureus (MRSA) infections.69 Compared to most other antibiotic 
resistance such as resistance to penicillin 6 requiring the activity of only one gene product, 
β-lactamase enzyme, resistance to vancomycin 13 needs five genes, vanS, R, H, A, X,70 
and takes a longer time to develop. This may be related to its unusual mode of action that 
precludes simple point mutations as a resistance mechanism. However, vancomycin-
resistant staphylococci and enterococci have emerged and are spreading with unexpected 
rapidity.69  
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The mechanism of resistance to vancomycin 13 involves the presence of operons that 
encode enzymes for synthesis of low-affinity precursors, in which the C-terminal D-Ala 
residue 22 is replaced by D-lactate (D-Lac) 33 or D-serine (D-Ser) 34, thus modifying 
the vancomyin-binding target.71 D-Ala-D-Lac 33 variation results in the replacement of 
the amide NH in D-Ala-D-Ala 22 with the ester oxygen and the loss of one hydrogen-
bonding interaction between vancomycin 13 and the substrate. This action causes a 
1,000-fold decrease in affinity. While the change of the C-terminal methyl side chain in 
D-Ala-D-Ala 22 to the -CH2OH in D-Ala-D-Ser 34 causes only a 6-fold lower affinity 
for vancomycin 13, possibly due to steric hindrance (Figure 22).72-74 
 
 
Figure 22: D-Ala-D-Ala 22 is replaced by D-Ala-D-Lac 33 or D-Ala-D-Ser 34. 
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Interestingly, high-affinity binding to the D-Ala–D-Lac 33 substrate can be restored by 
introducing an amidine group into the vancomycin molecule 13 opposite the ester oxygen 
in the substrate.73 The amidine derivative 35 is reported to inhibit both vancomycin-
sensitive and vancomycin-resistant bacteria (Figure 23). If a practical and cost-effective 
method can be found to produce this derivative 35 to overcome vancomycin resistance, 
it should be of great clinical value.73,75 
 
 
Figure 23: Vancomycin 13 can be modified to overcome bacterial resistance. 
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1.4.6 Resistance to Rifampicin 
Clinical and laboratory studies of rifampicin 21 initially targeted a broad spectrum of 
susceptible bacteria and the resistance was reported in laboratory studies and in patients 
who received monotherapy with rifampicin 21. Resistance rates to rifampicin 21, 
determined in the laboratory, have ranged from 10-10 to 10-7, depending on the organism 
and the methodology used.59 Resistance to rifampicin 21 nearly always due to a genetic 
change in the β subunit of bacterial RNA polymerase (RNAP). In the rifampicin resistant 
E. coli strain, the migration of β subunit in polyacrylamide gel electrophoresis was 
observed to be altered. Late on, separation and mixed reconstitution of enzymatically 
active core enzyme, using the subunits from susceptible and rifampicin resistant strains 
of E. coli and Bacillus subtilis, provided a more direct demonstration that resistance to 
rifampicin 21 was determined by the change in the β subunit.76,77 
 
Rifampicin resistance has been reported in different gram-negative urinary tract 
pathogens, in vitro and in treated patients, and in gonococci and meningococci in the 
laboratory and the clinic.59 Rifampicin resistance even occurred in tuberculosis patients 
who failed therapy when rifampicin 21 was the only active drug administered. Thus, 
when treating tuberculosis and other diseases, rifampicin 21 is almost always combined 
with other active antimicrobials to prevent the emergence of resistance.69,76 
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1.5 Repurposing Drugs 
Drug repurposing aims to address resistance issues in bacteria and improve the process 
of developing new treatments and cures for diseases. It is a process or strategy of 
developing or discovering new therapeutic uses for failed or already marketed drug, 
which maximizes the therapeutic value of a drug and increase the success rates.78,79 With 
the increasing market competition, pharmaceutical companies collaborated with 
biomedical research community are developing new drugs or new therapeutic uses from 
existing/old/available drugs, by applying less time consuming and less costly drug 
repurposing strategies, with the ultimate goal of identifying promising new treatments 
for patients. Examples of this will be highlighted in this section.79 
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1.5.1 Viagra 
Viagra is the brand name of sildenafil 36 which has been proven to be effective and safe 
for the treatment of erectile dysfunction. The development of sildenafil 36 began in 1986 
when chemists at Pfizer searched for a compound to treat hypertension, targeting 
augmentation of the renal tubular activity of atrial natriuretic peptide.80,81 Test 
compounds were shown to antagonize the activity of phosphodiesterase type 5 (PDE 5), 
resulting in vasodilation and platelet inhibition, turning their focus to treatment of angina. 
Trials in angina were disappointing but some patients reported the surprising and 
unexpected side-effect of penile erections, leading to the development of sildenafil 36 as 
a treatment for erectile dysfunction (Figure 24).81  
 
 
 
Figure 24: The structures of sildenafil (Viagra) 36. 
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The action of Viagra is started from the moment of the sexual stimulation but does not 
cause uncontrollable erection. At the moment of the sexual arousal, nitric oxide (NO) 
from non-adrenergic, non-cholinergic (NANC) neurons or endothelial cells stimulates 
the activity of guanylate cyclase which produces cyclic guanosine monophosphate 
(cGMP) from guanosine triphosphate (GTP).82,83 Viagra inhibits PDE 5 enzyme to 
protect cGMP from degradation, so that the concentration of the important ingredient 
cGMP is increased in the cavernous body. The modulation of ion channel activity by 
increased cGMP leads to smooth muscle relaxation of the intimal cushions of the helicine 
arteries, which eventually leads to vasodilation and increased inflow of blood into the 
corpora cavernosa of the penis, causing an erection (Figure 25).81 
 
 
 
Figure 25: Mechanism of vasodilatory effect of Viagra. 
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1.5.2 Colesevelam 
Colesevelam 37 is another example of drug repurposing. It is sold by different 
pharmaceutical companies under varying brand names. In the United States, it is 
marketed by Daiichi Sankyo as Welchol and in Canada, it is marketed by Valeant as 
Lodalis. Elsewhere, it is marketed by Genzyme as Cholestagel (Figure 26).84 
 
 
Figure 26: Structure of colesevelam 37, the active pharmaceutical ingredient in Welchol. 
 
Colesevelam (Welchol) 37 is originally used as an adjunct to diet and exercise for the 
reduction of low-density lipoprotein cholesterol (LDL-C) in the setting of 
hyperlipidemia.85 As a class of medications called bile acid sequestrants, colesevelam 
(Welchol) 37 works by binding bile acids within the intestinal tract due to its chemical 
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structure (hydrophilic polymer backbone with hydrophobic side chains) and removing 
these bile acids from the body via elimination within the faeces.84,85 This binding action 
prevents the body from recycling the bile acids from the intestines in its usual manner. 
By preventing the recycling process, the liver must therefore produce new bile acid by 
taking cholesterol from the blood stream which results in lowering cholesterol blood 
levels (Figure 27).86,87 
 
 
Figure 27: Mechanism of action of Welchol. 
 
Currently, the use of colesevelam (Welchol) 37 is expanded to treat diabetes mellitus 
type 2. In clinical studies in patients with type 2 diabetes, colesevelam 37, added to 
existing metformin, sulfonylurea or insulin therapy, reduced hemoglobin A1c (HbA1c) by 
a mean of 0.5% and LDL-C by 13 - 17%.88,89 The mechanism by which colesevelam 37 
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improves glycemia control in adults has not been yet understood, but it is clear that the 
drug works within the digestive tract since it is not absorbed into the rest of the body.89 
 
 
1.5.3 Benzodiazepines 
Benzodiazepines 38 are a group of medications which have been used since the 1960s to 
treat severe muscle spasms, tremors, acute seizures, insomnia, and alcohol and drug 
withdrawal symptoms, but their main use is still for the treatment of anxiety disorders. 
The four widely used benzodiazepines in clinical anaesthesia are the agonists midazolam 
38, diazepam 39, lorazepam 40 and the antagonist flumazenil 41 (Figure 28).90 
 
 
 
Figure 28: The structures of four benzodiazepines midazolam 38, diazepam 39, lorazepam, flumazenil 41 
and gamma aminobutyric acid 42. 
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Benzodiazepines work by increasing the effect of a chemical called gamma aminobutyric 
acid (GABA) 42, the main inhibitory neurotransmitter in the brain. In the central nervous 
system, benzodiazepines enhance responses to the inhibitory neurotransmitter GABA 42 
by opening GABA-activated chloride channels and allowing chloride ions to enter the 
neuron. This action allows the neuron to become negatively charged and resistant to 
excitation, which leads to the various anti-anxiety, sedative or anti-seizure activity seen 
with these drugs.91 Benzodiazepines are very effective in the short term but they may 
stop working if people take them continuously for more than a few months. This is 
because the brain adjusts to their effect and may be hypersensitive to natural brain 
chemicals when they are stopped which may even cause drug dependence.92.93 
 
In addition to their action on the central nervous system, benzodiazepines have a dose-
dependent ventilatory depressant effect and they also cause a modest reduction in arterial 
blood pressure and an increase in heart rate as a result of a decrease of systemic vascular 
resistance.90,94  
 
However, with increased potency of benzodiazepines comes an increase in the risk of 
undesired effects. The adverseness includes not only common side effects like 
drowsiness, lethargy and fatigue, but also severe central nervous system toxicity and 
delirium.95 Cognitive impairment is usually more prominent in elderly populations 
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because age-related decline in the function of homeostatic mechanisms in the body, 
notably the central nervous system, liver, and kidneys, reduces the ability to metabolize 
and eliminate drugs. This problem can lead to toxic accumulation of benzodiazepines 
and their breakdown products, the result of which may manifest in morbidity and even 
mortality.96 
 
Anterograde amnesia and sexual abuse can occur due to the amnesic properties of 
benzodiazepines, especially at high doses.97 In one case of drug-facilitated sexual assault, 
woman ingested benzodiazepins in conjunction with alcohol consumption and did not 
have any recollection of the event, but police found the metabolite of benzodiazepine in 
the urine sample.98 
 
Recently, researchers have examined alternatives to benzodiazepines and are addressing 
the issue of possible adverse effects in patients who use the drugs for long periods.91 It is 
necessary for prudent clinician to weigh the benefits and risks when prescribing this class 
of agents.95 
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1.6 Previous Work 
Previous work in the department involved the preparation of a variety of substituted 
benzodiazepines for a proof of concept study into their antibacterial activity. One of these 
compounds has been demonstrated to be an effective agent against some gram-positive 
cocci, such as Listeria monocytogenes, Staphylococci epidermidis and Staphylococcus 
aureus (Figure 29).  
 
 
 
Figure 29: MIC results for 3-((perfluoropyridin-4-yl) amino)-5-phenyl-1,3-dihydro-2H-benzo[e][1,4] 
diazepin-2-one 43. 
 
Unique to this molecule 43 is the inclusion of a fluoropyridine molecule which acts as an 
aromatic ring bio-isostere with differing physical properties and synthetic advantages 
over aromatic rings. Low-molecular-weight polyfunctional heteroaromatic compounds 
can be excellent candidates for benzodiazepines which are privileged structures since 
heteroaromatic structural subunits are present among a large number of natural products 
and around 70% of them are orally available.99 
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The use of fluorine as a design component is supported by its key features: low steric 
impact, high electronegativity, the ability to participate in hydrogen bonding and the 
inherent carbon-fluorine bond stability. Perfluorinated heteroaromatic derivatives are 
highly reactive towards nucleophiles owing to the presence of several highly 
electronegative fluorine atoms.99,100 
 
In any case, fluorine as a substituent in pyridine rings remains relatively understudied 
and the effects upon drug properties undocumented. As a result of these initial studies, 
this project plans to synthesize a variety of substituted benzodiazepines containing the 
fluoropyridine moiety to investigate how changing the core pharmacophore through the 
introduction of substituents around both aromatic cores to test the effects on their 
antibacterial activity (Figure 30). 
 
 
Figure 30: Substituted benzodiazepines containing the fluoropyridine moiety. 
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2.0 Results and Disscussion 
 
2.1 Introduction 
This chapter details the work undertaken in the area of substituted benzodiazepines and 
their biological properties in medical chemistry. The aim of this work was to synthesize 
some selective benzodiazepines substituted by fluoropyridine components and 
investigate structure-activity-relationship around the benzodiazepine core. To do this, we 
undertook a retrosynthetic analysis of the structure to determine the best method for the 
synthesis of the cores. 
 
 
2.2 Retrosynthetic Analysis 
The retrosynthetic analysis begins by disconnecting the benzodiazepine 44 from the 
fluoropyridine component at the nitrogen-aryl bond to give benzodiazepine core 45 and 
pentafluoropyridine 46 (Scheme1).  
 
 
Scheme 1: Retrosynthetic analysis of target molecule 44. 
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Further analysis of the benzodiazapine core 45 was undertook and revealed that the 
consecutive disconnections of the seven-membered heterocycle at the carbon-nitrogen 
single bond and the peptide bond would give 2-aminobenzophenone derivative 50 and 
2,2-diaminoacetic acid 51 (Scheme 2).  
 
 
Scheme 2: Disconnection of benzodiazepine core 45. 
 
With this analysis in mind, a search of the literature revealed several synthesis which 
follow this analysis. 
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2.2.1 Ellman’s Approach 
This approach involves the solid-phase synthesis of 1,4-benzodiazepine derivatives. The 
1,4-benzodiazepin-2-one derivatives were initially constructed from three separate 
components: 2-aminobenzophenones, amino acids, and alkylating agents. The 
substituted 2-N-Fmoc aminobenzophenones are coupled to the acid-cleavable (4-
(hydroxymethyl)phenoxy)acetic acid (HMP) linker which may be attached by either a 
hydroxyl or a carboxyl group on either aromatic ring of the aminobenzophenones.101 
Employing standard amide bond formation methodology, the linker-derivatized 
aminobenzophenones 52a, 52b are then coupled to the solid support (Scheme 3). 
 
Scheme 3: The couples of the linker-derivatized aminobenzophenones 52a, 52b with the solid support. 
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The synthesis of benzodiazepines on solid support begins with removal of the 9-
fluorenyl-methoxycarbonyl (Fmoc) protecting group from the aminobenzophenone 53 
by treatment with piperidine in DMF. Then the unprotected 2-aminobenzophenone is 
coupled with the α-N-Fmoc amino acid fluoride to give the amide product 54. Standard 
activation methods for solid-phase peptide synthesis are not successful for this coupling 
step because of the poor basicity and nucleophilicity of 2-aminobenzophenones. 
However, the activated R-N-Fmoc amino acid fluoride developed by Carpino couple 
efficiently to provide the amide products 54 even for electron-deficient 2-
aminobenzophenone derivatives (Scheme 4).102 
 
 
Scheme 4: Synthesis route of 1,4-benzodiazepine product 57. 
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The Fmoc protecting group is then removed via treatment with piperidine in DMF again, 
and the resulting free amine is treated with 5% acetic acid in N-methyl-2-pyrrolidinone 
(NMP) at 60 °C to provide the benzodiazepine derivatives 55. It is then possible to 
alkylate the anilide by using the excess base (lithiated acetanilide or lithiated 5-
(phenylmethyl)-2-oxazolidinone) and an alkylating agent to provide the fully derivatised 
1,4-benzodiazepines 56. Treatment with the volatile acid cleavage cocktail trifluoroacetic 
acid (TFA)/Me2S/H2O (95:5:5) finally affords the 1,4-benzodiazepine product 57 in high 
yield.103,104 
 
However, not many appropriately functionalized 2-aminobenzophenones are readily 
accessible. To increase the diversity of 1,4-benzodiazepin-2-ones available for solid 
support synthesis, Ellman et al modified the premium of the approach employing the 
Stille coupling reaction to synthesize a variety of 2-aminoaryl ketones on solid support.105  
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The support-bound 2-(4-biphenyl)isopropyloxycarbonyl (Bpoc) protected 
(aminoaryl)stannane 58 is prepared in five steps from commercially available starting 
material, and coupling to support is accomplished using the acid-cleavable HMP linker. 
The Stille coupling reaction can be carried out with a variety of acid chlorides in the 
presence of the catalyst Pd2(dba)3•CHCl3. The Bpoc group is cleaved by brief treatment 
with 3% TFA in CH2Cl2 solution for 5 min, affording the support-bound aminoaryl 
ketone 59 which were further incorporated into 1,4-benzodiazepine derivatives 60 
according to previously described synthesis sequence (Scheme 5).102 
 
 
Scheme 5: Stille coupling reaction is employed to synthesize aminoaryl ketone 59. 
 
By employing the versatile solid-phase synthesis, the yields for the benzodiazepine 
products are considerable (vary from 52% to 82 %). However, this sequence requires 
over seven steps and many different reagents, which is lengthy and inefficient. 
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2.2.2 Huang’s Approach 
Huang and others have significantly improved the efficiency and diversity for the 
synthesis of new benzodiazepines using a convergent Ugi-4CR (four-component reaction) 
followed by deprotection and intramolecular cyclization (Table 1).106  
 
 
Entry X Y R1 Anchor Yields 
66a H Ph tBu Phe 41 % 
66b H Ph tBu Leu 41 % 
66c H Ph cyclohexyl Phe 50 % 
66d H Ph cyclohexyl Leu 69 % 
66e H Me tBu Phe 44 % 
66f H Me tBu Leu 46 % 
66g 4-Cl Ph tBu Phe 32 % 
66h 4-Cl Ph tBu Leu 43 % 
66i H Ph tBu Trp 26 % 
66j H Ph tBu Tyr 29 % 
66k H Ph cyclohexyl Trp 65 % 
66l H Ph cyclohexyl Tyr 60 % 
66m H Ph benzyl Trp 22 % 
Table 1: Synthesis of anchor-directed 1,4-benzodiazepines 66a-m. 
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In the first step (Ugi), the aminophenylketone 61 serves as an amine component for the 
Ugi-4CR together with an isocyanide 62, N-Boc-amino-acid 63 and formaldehyde 64. 
The Boc protection group of the Ugi product 65 is cleaved in the second step 
(deprotection). Then the free amine group is condensed with the orthogonal ester group 
to form the 1,4-diazepine ring in the third step (cyclization).106,107 Phenylalanine, leucine, 
tryptophan and tyrosine, which are abundant in the protein-protein interaction interface, 
were selected as examples in this synthetic sequence. 
 
Compounds 66a-m with four points of diversity were isolated by chromatography in 22-
69 % yield over two steps. This approach provides access to benzodiazepines in 
acceptable yields, however is unable to provide the wanted amino group at the “anchor” 
position and possesses extra diversity at the amide nitrogen. 
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2.2.3 Spencer’s Approach 
According to Spencer’s research, C3 and C5 substituted benzodiazepines 68 were 
synthesised from readily available 2-aminophenylketones 67 in a three step process 
involving treating with 2-ethoxy-1-ethoxycarbonyl-1,2-dihydroquinoline (EEDQ) and 
Boc-NHCH(R2)CO2H at room temperature (Scheme 6).
108,109  
 
 
Scheme 6: Synthesis of N1-substituted benzodiazepine analogues 69. Reagents and conditions: (a) Boc-
NHCH(R2)CO2H, EEDQ, DCM, rt; (b) TFA, DCM, rt; (c) CH3COONH4, AcOH, rt; (d) NaH, R3Br or R3I, 
DMF. 
 
By treating the compound 68 with sodium hydride and alkylation with the appropriate 
alkyl or benzyl halide, the N1-substituted benzodiazepine analogues 69 were obtained. 
Differently, in order to add NO2 group to the aromatic ring, 68 needed to be treated with 
KNO3 in concentrated H2SO4 at 0 ℃ before the final step (Scheme 7).109 
 
 
 
Scheme 7: Synthesis of nitro benzodiazepine analogues 70. 
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Although the sequence to three-step synthesis of benzodiazepine derivatives is not very 
complex with the acceptable yields of substituted benzodiazepines 68 varying from 22 % 
to 71 %, the amino group at the R3 position is still unavailable. R2 labelled different 
function groups such as H, Bn, CH2(Ph)2 and CH2CN, but no amino group. 
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2.2.4 Bock’s Approach 
Bock and co-workers reported two preparations of 1,4-benzodiazepines in 1987. The first 
of these routes involved construction of the N1-substituted 1,4-benzodiazepine nucleus 
followed by introduction of the 3-amino functionality which is the substrate we want 
(Scheme 8).110  
 
 
 
Scheme 8: Bock’s synthetic route to 3-amino-1-methyl-5-phenyl-1,3-dihydro-2H-benzo[e][1,4]diazepin-
2-one 75. Reagents and conditions: (a) BrCOCH2Br, CH2Cl2-H2O, -10-23 ℃, 4 h; (b) NH3 (g), CH3OH, -
10 - 15 ℃, 2 h, then 65 ℃, 2 h; (c) CH3Cl, NaOH (aq), toluene, Aliquat 336, 0-25 ℃, 4 h; (d)t-BuOK, i-
AmONO, toluene, -20-0 ℃, 45 min; (e) H2, 5 % Ru/C, CH3OH, 68-74 ℃, 40 psi, 24 h. 
 
Nevertheless, the two-step amination sequence required oxime formation and subsequent 
catalytic hydrogenation over a reduced ruthenium catalyst at elevated temperature and 
57 
 
pressure, leading to 48 % overall yield. The strict experimental conditions required 
increase the difficulty of this approach. 
 
The second route employed α-(isopropylthio)-N-(benzyloxycarbony1)glycine 76 as a 
masked aminoglycine synthon. The key synthetic step involved a novel mercury-
mediated displacement of the isopropylthiol group with ammonia to generate the aminal 
present in the 3-aminobenzodiazepine nucleus 79. A combination of α-(isopropylthio)-
N-(benzyloxycarbony1)glycine 76, isobutyl chloroformate, and N-methylmorpholine 
afforded the corresponding mixed anhydride which was then reacted in situ with 2-
aminobenzophenone 71 to give alkylthioglycine amide 77 in >90% yield. In the next 
critical step, the alkylthioglycine amide 77 was dissolved in dry tetrahydrofuran, 
saturated with ammonia and treated with 1.l equivalents of mercuric chloride. A 
continuous stream of ammonia gas into the reaction mixture served to complete the 
alkylthio displacement. The intermediate α-amino glycinyl amide 78 was obtained and 
conveniently dissolved in glacial acetic acid containing ammonium acetate and stirred at 
room temperature overnight (or 2.5 h at 55 ℃). In this way, 79 was obtained as a 
crystalline solid in 70-75% yield. To complete the synthesis, the carbobenzyloxy 
protecting group was removed under transfer hydrogenation conditions to give 30 as its 
formate salt. The free amine 30 was isolated after neutralization of the salt with sodium 
hydroxide solution (40 %) in methylene chloride in 86 % yield (Scheme 9).111 
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Scheme 9: Bock’s synthetic route to 3-amino-5-phenyl-1,3-dihydro-2H-benzo[e][1,4]diazepin-2-one 80. 
Reagents and conditions: (a) iso-BuOCOCl, N-methylmorpholine, CH2C12, 0 ℃, 15 min; 0 - 23 ℃, 12 h; 
(b) NH3 (g), HgCl2, THF, 0 - 23 ℃, 3 h; (c) NH4OAc, AcOH, 23 ℃, 12 h; (d) 10 % Pd/C, HCO2H (95 %) 
- CH3H (5:95, v/v), 45 ℃, 3 h. 
 
While higher yielding than the oxime route, this process suffers from the use of 
stoichiometric quantities of highly toxic mercuric chloride and the rather odoriferous 
nature of the displaced 2-propanethiol. 
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2.2.5 Our Synthetic Route 
Reported by Sherrill et al, the convenient high-yielding synthetic route, which is also the 
approach this project followed, is an improvement of Bock’s approach.112 Since an α,α-
diamino moiety is unstable and not easily available, in this work, α-benzotriazol-1-yl-N-
(benzyloxycarbonyl)glycine 81 served as the superior aminoglycine synthon.113 
Preliminary attempts to couple benzotriazole adduct 81 to 2-aminobenzophenone 71 with 
standard peptide coupling agents or via a mixed anhydride gave little or no reaction. 
However, in situ formation of the acyl chloride with oxalyl chloride and catalytic DMF 
followed by treatment with 2-aminobenzophenone 71 gave clean conversion to acyl 
amide 82 as assessed by TLC. The crude solution of 82 was treated directly with 
ammonia gas in a THF/methanol solvent mixture to provide amino ketone 83. Following 
solvent displacement into ethyl acetate, the benzotriazole byproduct was readily 
extracted with aqueous base and the crude amino ketone 83 was cyclized to provide 3-
[(benzyloxycarbonyl)aminol-1,4-benzodiazepine 84 in 73% overall yield from 2-
aminobenzophenone 71 without chromatography. Removal of the Cbz protecting group 
by treatment with saturated HBr in acetic acid and subsequent neutralization was effected 
in 88% yield to provide 3-amino-l,4-benzodiazepin-2-one 80 in 66% overall yield from 
2-aminobenzophenone 71 (Scheme 10). 
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Scheme 10: Our synthetic route to 3-amino-5-phenyl-1,3-dihydro-2H-benzo[e][1,4]diazepin-2-one 80. 
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2.3 Synthetic Route to Benzotriazole Substituted Amino Acid 
Based on the retrosynthetic analysis described in section 2.2, the first step of the synthesis 
was to prepare 2-(benzotriazol-1-yl)-N-(benzyloxycarbonyl)glycine 81 as starting 
material. The condensation of benzyl carbamate 85 with glyoxylic acid 86 and 
benzotriazole 87 proceeds easily. An equimolar ratio of the reactants in refluxing toluene 
are utilized to give the glyoxylic acid adduct 81 (Scheme 11).  
 
 
Scheme 11: Synthesis of stable 2-benzotriazol-1-yl-N-(benzyloxycarbonyl)glycine 81. 
 
Isolation of the product is convenient because of its sparing solubility and the solid 
product can be filtered off from the reaction mixture to obtain a high yield (91 %). This 
was advantageous as large quantities of this material were required for the synthesis of 
benzodiazepine cores. 
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2.4 Synthetic Route to Benzodiazepine Cores 
With the 2-benzotriazol-1-yl-N-(benzyloxycarbonyl)glycine 81 in place, several 
different 2-aminobenzophenone derivatives were employed. To begin, synthesis of the 
benzodiazepine core 84 was undertaken by repeating the experiments from Sherrill’s 
work, where by the condensation of 1.1 equivalents of 2-(benzotriazol-1-yl)-N-
(benzyloxycarbonyl)glycine 81 and one equivalent of 2-aminobenzophenone 71, 
utilising oxalyl chloride in DCM, gave rise to intermediate 82. The crude 82 was 
evaporated and treated in situ with ammonia in ethanol. This gave rise to 83 which was 
subsequently cyclised, following evaporation of NH3/ethanol, with ammonium acetate 
and acetic acid to give 84 in a yield of 34% (Scheme 12).  
 
 
Scheme 12: Synthesis of benzyl (2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl)carbamate 
84. 
 
The low yield (34 %) of benzodiazepine 84 could arise from several factors, such as 
incomplete condensation with 2-aminobenzophenone 71 which was observed by TLC. A 
possible reason for the incomplete reaction was the poor formation of the acyl chloride 
from the starting material 81 and volatile oxalyl chloride. To improve the yield of 84, the 
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equivalence of oxalyl chloride was increased from one equivalent to 1.5 equivalents. 
Nevertheless, this did not make a big difference, so the more reasonable explanation for 
the incomplete condensation was the possible decomposition of 81 in the reaction 
mixture. 
 
Different states of ammonia employed in the reaction also could lead to the low yield. 
Compared with the previous experiments saturated with ammonia gas, which might be 
more favourable for amination process, ammonia in liquid ethanol was used instead in 
this project. 
 
An additional reason for the low yield was that the previous experiments began with 28 
mmol reagents which was 40 times more than our starting materials. Thus, the lost 
amount of product in our work influenced the yield more severely. Some evidence for 
this reason was that when we first synthesized the bromo-substituted benzodiazepine 89 
with 0.7 mmol 2-amino-4’-bromobenzophenone 88, the yield of product was 38 %, but 
double amount of reagents afforded the yield of product 89 to be 50 % (Scheme 13). 
 
 
Scheme 13: Synthesis of benzyl (5-(4-bromophenyl)-2-oxo-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-
yl)carbamate 89. 
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In any event, we persevered with our synthetic approach to produce a series of 
benzodiazepine cores with a variety of substituents present in both aromatic rings.  
 
The first synthesis of the chloro-substituted benzodiazepine 91 began with 0.7 mmol 2-
amino-5-chlorobenzophenone 90. The product 91 was obtained by filtering the mixture 
of organic and aqueous layers at 0 - 5 ℃ only yielding to 18 %. The low yield was 
possibly by the reason that the chloro-substituted benzodiazepine 91 was soluble in the 
organic solution of ethyl acetate and diethyl ether and part of the product 91 was lost in 
the discarded filter liquor. Therefore, the second trial of this synthesis starting with 1.4 
mmol 2-amino-5-chlorobenzophenone 90 did not undergo filtration. Instead, the aqueous 
layer was removed and then the reaction mixture was concentrated in vacuo. When the 
organic solvent volatilized overnight, much more product crystalized and finally a 
solution of n-hexane and a small amount of ethyl acetate was applied to wash the product 
to afford the compound 91 with the yield of 46 % (Scheme 14). 
 
 
Scheme 14: Synthesis of benzyl (7-chloro-2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-
yl)carbamate 91. 
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Synthesized from the same amount (1.40 mmol) of 2-aminobenzophenone derivatives 88, 
92 and 93, the substituted benzodiazepines 89, 94 and 95 were more soluble than 84 and 
91 in the organic solution of ethyl acetate and diethyl ether. Thus, they cannot be obtained 
by filtration, and flash chromatography was employed to isolate them leading to a yield 
of 50 %, 49 % and 44 % respectively (Scheme 15). 
 
 
Scheme 15: Synthesis of the substituted benzodiazepines 89, 94 and 95. 
 
The substituted benzodiazepine 99 was successfully synthesized beginning with 2-
amino-2’,5-dichlorobenzophenone 96. The presence of the benzodiazepine 99 was 
confirmed by 1H NMR spectrum from the appearance of the peaks corresponding to the 
aryl groups (7.07-7.70 ppm, 13H), the NH group (6.68 ppm, 1H), CH group (6.45 ppm, 
1H),) and CH2 group (5.11 ppm, 2H). The mass spectrum also confirmed the right mass 
of benzodiazepines 99 at m/z 909 (2M+H+). Unfortunately, the yield was quite low and 
it had not been isolated because its polarity was close to the intermediate 97 as assessed 
by TLC which was one of the impurities in the synthetic crude product (Scheme 16). 
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Scheme 16: Synthesis of benzyl (7-chloro-5-(2-chlorophenyl)-2-oxo-2,3-dihydro-1H-benzo[e][1,4] 
diazepin -3-yl)carbamate 99. 
 
The coupling of benzotriazole 81 with (2-amino-5-chlorophenyl)(2,6-
difluorophenyl)methanone 100 or (2-amino-5-nitrophenyl)(2-chlorophenyl)methanone 
101 gave little or no reaction. The substituted benzodiazepines 102, 103 could not been 
obtained (Scheme 17).  
 
 
Scheme 17: Synthesis of the substituted benzodiazepines 102, 103 failed. 
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The coupling of benzotriazole 81 with 2-aminoacetophenone 104 and 2'-
aminoacetophenone 106 respectively were also attemped to prepare 105 and 107 with 
both of them successfully synthesized (Scheme 18).  
 
  
 
Scheme 18: Synthesis of benzyl (3-oxo-6-phenyl-2,3,4,5-tetrahydropyrazin-2-yl)carbamate 105 and 
benzyl (5-methyl-2-oxo-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl)carbamate 107. 
 
The presence of the compounds 105 and 107 was confirmed by 1H NMR and mass 
spectra. Both of them were not isolated and utilized directly in the next synthetic 
transformation. 
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2.5 Synthesis of Benzyloxycarbonyl Deprotected Product 
With a series of benzodiazepines 84, 89, 91, 94, 95, 105 and 107 in hand, the Cbz 
deprotected products 80 and 110 were obtained in 82 % and 71 % yields by treating 84, 
91 with hydrobromic acid in acetic acid. Aminobenzodiazepines 109 and 111 were not 
isolated and utilized directly in the final coupling reaction (Scheme 19).  
 
 
Scheme 19: Synthesis of the Cbz deprotected products 80, 109-111. 
 
By treating 95 with hydrobromic acid, aminobenzodiazepine 112 was obtained as a 
mixture of brominated products and the presence was confirmed by 1H NMR spectrum 
from the appearance of the peaks corresponding the NH group (7.82 ppm, 1H), the aryl 
groups (7.35-7.60 ppm, 8H) and the CH group (6.81 ppm, 1H). Analysis by mass 
spectrum detected the brominated molecular ions at m/z 446 (MNa+). However, the 
desired aminobenzodiazepine 113 was not obtained (Scheme 20). 
 
Scheme 20: Synthesis of the Cbz deprotected product 112. 
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The compound 115 was also synthesized successfully by deprotecting 105. Its presence 
was confirmed by 1H NMR spectrum from the appearance of the peaks corresponding 
the NH group (7.89 ppm, 1H), the aryl groups (7.29-7.54 ppm, 5H), the CH2 group (3.49 
ppm, 2H) and the CH group (2.17 ppm, 1H). Analysis by mass spectrum detected the 
molecular ions at m/z 188 (M-H-) (Scheme 21).  
 
 
Scheme 21: Synthesis of the Cbz deprotected product 115. 
 
The Cbz deprotecting of 107 was not smoothly carried out. Compound 107 did not react 
with HBr even when adding more reagents, raising the temperature or increasing reaction 
time, so the progress stopped here. 
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2.6 Final Coupling Reaction 
The final coupling of deprotected benzodiazepines with pentafluoropyridine 46 provided 
our target molecules 43, 116-118 with the final product 116 being obtained in a high 
yield (99 %) (Scheme 22).  
 
Scheme 22: Synthesis of the final products 43, 116, 117 with the fluoropyridine moieties. 
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Mechanistically, pentafluoropyridine 46 was attached to deprotected benzodiazepine 
core at the 3-amino position. Nevertheless, during the synthesis of bromide target 
molecule 118, the reaction rate was very low. Because pentafluoropyridine 46 was 
volatile, additional equivalents of pentafluoropyridine 46 and triethylamine were added 
to the uncomplete reaction after reacting overnight. As a result, the final product was the 
double coupled benzodiazepine derivative 118 (Scheme 23). 
 
 
Scheme 23: Synthesis of 5-(4-bromophenyl)-1-(perfluoropyridin-4-yl)-3-((perfluoropyridin-4-yl)amino)-
1,3-dihydro-2H-benzo[e][1,4]diazepin-2-one 118. 
 
 
 
 
 
72 
 
3.0 Biological Investigation of Final Compounds 
Biological screening was undertaken utilizing a plethora of bacteria. The range was 
inclusive of gram positive, gram negative and mycolata bacteria. Specifically we utilized 
Enterococcus faecium, Listeria monocytogenes, Staphylococcus aureus, Escherichia 
coli, Pseudomonas aeruginosa, Salmonella enterica subsp. enterica and Mycobacterium 
tuberculosis, many of which are causative agents for different diseases or illnesses, such 
as neonatal meningitis or endocarditis,114 listeriosis,115 sinusitis, food poisoning,116 
urinary tract infections,117 ventilator-associated pneumonia, various sepsis syndrome, 
typhoid118 and tuberculosis.119    
 
The compounds 43, 119-122 were prepared in the previous work with the unsubstituted 
compund 43 synthesized and retested in this project. The compounds range number were 
dissolved in DMSO at the concentration of 1.5 – 0.5 µg/ml and subjected to a standard 
REMA assay to calculate the minimum inhibitory concentration (MIC, µM) utilizing 96-
well plates and resurin to visualize the results. MIC indicated that the standard 43 fighted 
against Bacillus subtilis, Listeria monocytogenes, Staphylococcus aureus, Streptococcus 
agalactiae, Streptococcus pyogenes and Mycobacterium tuberculosis, while the 
substitutions on the fluoropyridine moiety influenced the activity, so 119-121 only had 
effect on Mycobacterium tuberculosis. With ethoxy group connected to fluoropyridine, 
MIC of 121 against M. tuberculosis was similar to 43 (18.76 µM vs 18.40 µM 
respectively). Morpholine substitution on 119 slightly influences the MIC against M. 
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tuberculosis which was 25.67 µM. Methanesulphonamide substitution on 120 greatly 
weakened the activity against M. tuberculosis, and the MIC was 69.55 µM. 
 
The compounds 116, 117 substituted by chlorine and fluorine on the aromatic rings did 
not decrease the activity greatly. MIC of 116 against Bacillus subtilis was similar to 43 
(19.98 µM vs 18.40 µM respectively), and the MIC of 117 was larger (35.34 µM). The 
MICs of 116 (19.98 µM) and 117 (17.67 µM) against Staphylococcus aureus were 
around double of 43 (9.20 µM). The MICs of three against Streptococcus agalactiae were 
almost the same (18.40 µM, 19.98 µM and 17.67 µM respectively). The MICs of 43 
against Streptococcus pyogenes and Mycobacterium tuberculosis both were 18.40 µM, 
and for 116, 117, they doubled to 39.97 µM and 35.34 µM. The only big difference was 
that the MICs of 43 and 116 against Listeria monocytogenes were 36.80 µM and 39.97 
µM respectively, but 117 was inactive. 
 
However, when N1 was coupled with pentafluoropyridine 46, the compounds 122, 118 
were inactive to all tested bacteria. Therefore, it is important to keep the N1 unsubstituted 
as highlighted (Entry 117 vs Entry 118). Steric hindrance may also contribute to the 
inactivation of 118 to all tested bacteria. Fluorine atom was not much bigger than 
hydrogen so the compound 117 did not make a big difference from 43. On the same 
aromatic ring, bromine atom was very large and probably influenced the antibacterial 
efficiency of 118 (Figure 31, Table 2). 
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Figure 31: Structures of compounds 43, 116-122 
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MIC (µM) 
 119 - - - - - - - - - - 25.67 
120 - - - - - - - - - - 69.55 
121 - - - - - - - - - - 18.76 
43 18.40 - 36.80 9.20 18.40 18.40 - - - - 18.40 
116 19.98 - 39.97 19.98 19.98 39.97 - - - - 39.97 
117 35.34 - - 17.67 17.67 35.34 - - - - 35.34 
122 - - - - N/T - - - - N/T N/T 
118 - - - - - - - - - - - 
 - = no activity; N/T = not tested. 
Table 2: MIC results for compounds 43, 116-122. 
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4.0 Conclusion and Further Work 
 
4.1 Conclusion 
The aim of this project was to synthesize a variety of substituted benzodiazepines 
containing the unique fluoropyridine moiety and investigate the structure-activity 
relationship surrounding the benzodiazepine core in relation to their antibacterial activity. 
Towards this end, several important methods to the synthesis of benzodiazepine cores 
have been studied and the most suitable approach was utilized and improved in our work. 
 
In respect to benzodiazepine core synthesis, the starting material 81 was synthesized via 
a one-pot reaction and was treated with oxalyl chloride and catalytic DMF to form the 
acyl chloride. Then it was coupled to 2-aminobenzophenone derivative 50 to give acyl 
amide which was treated directly with ammonia solvent to provide amino ketone. Follow 
on, the cyclization of amino ketone provided the benzodiazepine core 123. To remove 
the Cbz protecting group, the compound 123 was treated with saturated HBr in acetic 
acid to provide Cbz deprotected product 45. Finally, coupling of deprotected 
benzodiazepine 45 with pentafluoropyridine 46 afforded our target molecule 44 (Scheme 
24). 
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Scheme 24: Synthetic route to our target molecule 44. 
 
The final compounds 43, 116-118 were successfully synthesized and tested against a 
variety of bacteria. Compared with the biological investigation results of the compounds 
in the previous work, some valuable conclusions can be made: the substitutions on the 
fluoropyridine moiety of target molecules greatly influence the activity against bacteria 
while the substitutions by chlorine and fluorine on the aromatic rings did not decrease 
their antibacterial efficiency. The coupling of pentafluoropyridine 46 on N1 contributed 
to the inactivation to all tested bacteria with steric hindrance possibly also influence the 
antibacterial efficiency. 
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4.2 Further Work 
Following these studies, the synthetic route to benzodiazepine cores can be further 
improved to increase the yields. In that way, the benzodiazepine 99 is likely to be 
synthesized and isolated in a large quantity. In addition, several possible alternative 
strategies that we have not used for the synthesis remain to be explored. The formation 
of the benzodiazepines 102 and 103 may be available using different methods (Figure 32)  
 
 
Figure 32: The structures of benzodiazepines 99, 102 and 103. 
 
The synthesis of target molecules 43, 116-118 in this project was a big success and most 
of them showed great biological activity against a plethora of gram positive, gram 
negative and mycolata bacteria. Therefore, it is worth trying the synthetic route on 
different 2-aminobenzophenone derivatives. More target compounds with fluoropyridine 
moieties ought to be prepared and biologically investigated. 
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5.0 Experimental Procedures 
 
5.1 General Procedures 
All sensitive reactions were carried out in dried glassware under a nitrogen atmosphere 
unless otherwise stated. 
 
Solvents 
Solvents were obtained from an Innovative Technology Solvent Purification System. In 
cases where mixtures of solvents were utilised, the ratios refer to the volumes used. 
 
Reagents 
Reagents were used as supplied unless otherwise stated.  
 
Chromatography 
Reactions were monitored using thin layer chromatography (TLC) on precoated glass-
backed plates (silica gel 60Å F254). Materials were visualized by UV radiation at 254 nm, 
or by staining with phosphomolybdic acid in ethanol or potassium permanganate in water. 
Purification of products was performed by flash column chromatography using normal 
phase silica gel 40-63µm 60Å. 
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Melting point 
All melting points were determined using Stuart Digital Advanced Melting Point 
Apparatus (SMP30). 
 
IR spectroscopy 
Infrared spectra were recorded using a Diamond ATR (attenuated total reflection) 
accessory (Golden Gate) on a Perkin-Elmer FT-IR spectrometer (Spectrum Two). 
 
NMR spectroscopy 
1H NMR spectra were recorded in CDCl3 or DMSO on Varian Mercury-200, Bruker 
Avance-400, Varian Inova-500 or Varian VNMRS 700 instruments and are reported as 
follows; chemical shift δ (ppm) (number of protons, multiplicity, coupling constant J 
(Hz), assignment). Residual protic solvent CHCl3 (δH = 7.26 ppm) or DMSO (δH = 2.50 
ppm, 3.33 ppm) was used as the internal reference. 13C NMR spectra were recorded at 
176 MHz, using the central resonance of CDCl3 (δC = 77.0 ppm) as the internal reference. 
19F NMR spectra were recorded at 376 MHz on Varian VCR-400. All chemical shifts are 
quoted in parts per million relative to the internal reference and coupling constants are 
given in Hertz (Hz). Assignment and determination of stereochemistry were carried out 
using COSY, HSQC, HMBC and NOESY experiments. 
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Mass spectroscopy 
Electrospray mass spectra (ES) were obtained on a Micromass LCT mass spectrometer. 
Gas Chromatography Mass spectra (GC-MS:EI, Cl) were taken using a Thermo-Finnigan 
Trace within a 25 cm column connected to a VG Mass Lab Trio 1000. High resolution 
accurate mass measurement was performed on a LTQFT mass spectrometer (Thermo 
Finnigan Corporation) using flow-injection electrospray ionization at the Universtiy of 
Durham. 
 
 
5.2 Experimental Details 
 
2-(Benzotriazol-1-yl)-N-(benzyloxycarbonyl)glycine 81 
 
 
 
Benzyl carbamate 85 (1.51 g, 10.0 mmol), benzotriazole 87 (1.19 g, 10.0 mmol) and 
glyoxylic acid 86 monohydrate (0.92 g, 10.0 mmol) were dissolved in toluene (30 ml). 
The reaction mixture was stirred and refluxed in a Dean-Stark apparatus for 2 h. The 
temperature was set at 120 °C in the beginning and then slowly raised up to 150 °C in 
order to evaporate the water. After refluxing, the mixture was cooled down to room 
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temperature and the product precipitated. The product was filtered and washed with ether. 
It was left to dry in the air overnight to afford the title compound 81 as a white solid 
(2.97 g, 91 %). Rf 0.5 (EtOAc/pyridine/H2O/AcOH 30:10:5:34); m.p. 156 - 160 °C ; νmax 
(ATR) 3437-3221 (broad-OH), 2939, 1716 (C=O), 1641 (C=O), 1527, 1495, 1456, 1416, 
1364, 1345, 1305, 1282, 1250, 1227, 1168, 1147, 1105, 1052, 990, 936, 903 cm-1; δH 
(400 MHz, DMSO) 9.34 (1H, d, J 8, CONH), 8.06 (1H, d, J 8, NCHN), 7.17-8.00 (9H, 
m, Ar-H), 5.05 (2H, m, OCH2-Ar); m/z (ES
+) 327 (MH+), 349 (MNa+), 653 (2M+H+), 
675 (2M+Na+); all data agree with those reported in the literature. 
 
1.3-Dihydro-5-phenyl-3(R,S)-[(benzyloxycarbonyl)amino]-2H-1,4-
benzodiazepin-2-one 84 
 
 
 
Stage 1 
2-(Benzotriazol-1-yl)-N-(benzyloxycarbonyl)glycine 81 (0.25 g, 0.77 mmol) was 
dissolved in anhydrous THF (2.5 ml) under N2 and cooled to 0 - 5 °C with an ice-water 
bath. Oxalyl chloride (2 M in methyl chloride, 0.38 ml, 0.77 mmol) was added to the 
glycine solution followed by a drop of anhydrous DMF to start the reaction. After 
maintaining the reaction at 0 - 5 °C for 2 h, a solution of 2-aminobenzophenone 71 (0.14 
g, 0.69 mmol) and 4-methylmorpholine (0.15 ml, 1.54 mmol) in anhydrous THF (0.75 
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ml) was added dropwise to the reaction mixture by syringe. Then the ice-water bath was 
removed and the reaction was allowed to warm to room temperature. The reaction slurry 
was filtered and the filter cake was washed with a small amount of anhydrous THF. The 
mother liquor containing acyl amide was used directly in the next reaction.  
 
Stage 2 
Ammonia solution (2 M in ethanol, 2.1 ml, 4.14 mmol) was added to the acyl amide from 
the last step under N2 to react overnight. Ethyl acetate (30 ml) was added to the reaction 
solution, which was later washed twice with aq. NaOH (1 M, 2 x 15 ml). The combined 
aqueous layers were back-extracted with ethyl acetate (20 ml). The organic layers were 
combined, washed twice with brine (2 x 15 ml). It was then dried over anhydrous MgSO4, 
filtered and concentrated in vacuo.  
 
The crude amine (0.33 g) was combined with ammonium acetate (0.25 g, 3.24 mmol) 
and then they were dissolved in glacial acetic acid (5 ml, 87.43 mmol) under N2. The 
reaction mixture was allowed to stir at room temperature overnight and then concentrated 
in vacuo. Ethyl acetate (1.25 ml) and diethyl ether (3.75 ml) were added to the mixture. 
Aq. NaOH (1 M) was also added until the PH of the aqueous layer was greater than 8. 
After that, the mixture was cooled to 0 - 5 °C with an ice-water bath and filtered. The 
product was washed with water and diethyl ether and dried in the air over weekend to 
afford the title compound 84 as a light brown solid (91 mg, 34 %). Rf 0.4 (n-
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hexane/EtOAc 7:3); δH (400 MHz, CDCl3) 8.08 (1H, s, CONH), 7.12-7.58 (14H, m, Ar-
H), 6.59 (1H, d, J 8, NH-Cbz), 5.36 (1H, d, J 8, NCHN), 5.17 (2H, m, OCH2-Ar) ; m/z 
(ES+) 386 (MH+), 408 (MNa+), 771 (2M+H+), 793 (2M+Na+); all data agree with those 
reported in the literature. 
 
3-Amino-5-phenyl-1,3-dihydrobenzo[e][1,4]diazepin-2-one 80 
 
 
 
1.3-Dihydro-5-phenyl-3(R,S)-[(benzyloxycarbonyl)amino]-2H-1,4-benzodiazepin-2-
one 84 (60 mg, 0.16 mmol) was dissolved in the hydrobromic acid solution (33 wt. % in 
acetic acid, 5 ml, 86.52 mmol). The reaction solution was stirred and refluxed at 70 °C 
for 30 min. Then the temperature was raised to 80 °C and maintained for another 30 min. 
After refluxing, the mixture was cooled to ambient temperature, diluted with anhydrous 
diethyl ether (5 ml) and stirred for 30 min. There was no slurry formed because of too 
small amount of starting material. The solvent was evaporated and anhydrous diethyl 
ether (5 ml) was added to the mixture again. The aq. K2CO3 (5 % w/v, 10 ml) and ethyl 
acetate (10 ml) containing 2-propanol (0.5 ml) and dichloromethane (0.5 ml) were added 
to the reaction mixture. Then the free base was isolated by removing the basic aqueous 
layer. The organic layer was dried over anhydrous MgSO4, filtered and concentrated in 
85 
 
vacuo. The title compound 80 was obtained as a yellow solid (32 mg, 82 %). Rf 0.7 (n-
hexane/EtOAc 7:3); δH (400 MHz, DMSO) 11.12 (1H, s, CONH), 8.80 (2H, s, NH2), 
7.03-7.58 (9H, m, Ar-H), 4.90 (1H, s, NCHN); m/z (ES+) 252 (MH+), 274 (MNa+), 525 
(2M+Na+); all data agree with those reported in the literature. 
 
3-((perfluoropyridin-4-yl)amino)-5-phenyl-1,3-dihydro-2H-benzo[e][1,4] 
diazepin-2-one 43 
 
 
 
Stage 1 
1.3-Dihydro-5-phenyl-3(R,S)-[(benzyloxycarbonyl)amino]-2H-1,4-benzodiazepin-2-
one (77 mg, 0.20 mmol) 84 was dissolved in the hydrobromic acid solution (33 wt. % in 
acetic acid, 5 ml, 86.52 mmol). The reaction solution was stirred and refluxed at 70 °C 
for 30 min. Then the temperature was raised to 80 °C and maintained for another 30 min. 
After refluxing, the mixture was cooled to ambient temperature, diluted with anhydrous 
diethyl ether (5 ml) and stirred for 30 min. There was no slurry formed because of too 
small amount of starting material. The solvent was evaporated and anhydrous diethyl 
ether (5 ml) was added to the mixture again. The aq. K2CO3 (5 % w/v, 10 ml) and ethyl 
acetate (10 ml) containing 2-propanol (0.5 ml) and dichloromethane (0.5 ml) were added 
to the reaction mixture. Then the free base was isolated by removing the basic aqueous 
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layer. The organic layer was dried over anhydrous MgSO4, filtered and concentrated in 
vacuo. The 3-amino-5-phenyl-1,3-dihydrobenzo[e][1,4]diazepin-2-one was obtained as 
an orange solid (67 mg) and used directly in the next step. 
 
Stage 2 
Pentafluoropyridine 46 (0.05 ml, 0.46 mmol) was added to the crude compound (50 mg) 
from the last stage and they were dissolved in dichloromethane (2 ml). Triethylamine 
(0.10 ml, 0.72 mmol) was added to the reaction solution which was later stirred under N2 
at room temperature overnight. The resulting solution was diluted with dichloromethane 
(10 ml) and then washed twice with water (2 x 10 ml). The organic layer was dried over 
anhydrous MgSO4, filtered and concentrated in vacuo. The crude compound was 
obtained as a brown gum (42 mg). Flash chromatography (n-hexane, n-hexane/EtOAc 
[9:1]) afforded the title compound 80 as a white solid (23 mg, 39 %). Rf 0.4 (n-
hexane/EtOAc 7:3); m.p. 221 - 223 °C; νmax (ATR) 3355, 3196, 3067, 2907, 1698 (C=O), 
1647, 1601, 1579, 1546, 1478, 1447, 1428, 1411, 1384, 1328, 1275, 1227, 1185, 1170, 
1160, 1131, 1083, 1014, 972, 934 cm-1; δH (400 MHz, CDCl3) 8.41 (1H, s, CONH), 7.20-
7.66 (9H, m, Ar-H), 6.70 (1H, d, J 8, NH-Py), 5.41 (1H, d, J 8, NCHN); δC (176 MHz, 
CDCl3) 168.1 (C=O), 167.6 (C-Ph), 138.3 (Py-C-NH), 136.8 (ipso-Ar-C), 132.6 (C-F × 
2), 131.5 (C-F × 2), 131.0 (Ar-C, ipso-Ar-C), 129.7 (Ar-C × 2), 128.4 (Ar-C × 2), 127.5 
(ipso-Ar-C), 124.7 (Ar-C × 2), 121.4 (Ar-C × 2), 70.1 (NCHN); m/z (ES+) 401 (MH+), 
423 (MNa+); HRMS (ES+) Found MH+, 401.1023 (C20H13F4N4O requires 401.1025). 
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Benzyl (7-chloro-2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl) 
carbamate 91 
 
 
 
Stage 1 
2-(Benzotriazol-1-yl)-N-(benzyloxycarbonyl)glycine 81 (0.50 g, 1.53 mmol) was 
dissolved in anhydrous THF (5 ml) under N2 when cooling to 0 - 5 °C with an ice-water 
bath. Oxalyl chloride (2 M in methyl chloride, 0.77 ml, 1.53 mmol) was added to the 
glycine solution followed by a drop of anhydrous DMF to start the reaction. After 
maintaining the reaction at 0 - 5 °C for 2 h, a solution of 2-amino-5-chlorobenzophenone 
90 (0.32 g, 1.40 mmol) and 4-methylmorpholine (0.34 ml, 3.06 mmol) in anhydrous THF 
(1.5 ml) was added dropwise to the reaction mixture by syringe. Then the ice-water bath 
was removed and the reaction was allowed to warm to room temperature. The reaction 
slurry was filtered and the filter cake was washed with a small amount of anhydrous THF. 
After that, the mother liquor containing acyl amide was concentrated in vacuo. The crude 
acyl amide was used directly in the next step.  
 
Stage 2 
Ammonia solution (2 M in ethanol, 4.2 ml, 8.40 mmol) was added to the acyl amide from 
the last step under N2 to react overnight. Then ethyl acetate (30 ml) was added to the 
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reaction solution, which was later washed twice with aq. NaOH (1 M, 2 x 20 ml). The 
combined aqueous layers were back-extracted with ethyl acetate (20 ml). The organic 
layers were combined, washed twice with brine (2 x 20 ml). It was dried over anhydrous 
MgSO4, filtered and concentrated in vacuo.  
 
The crude amine (1.19 g) was combined with ammonium acetate (0.50 g, 6.49 mmol) 
and they were dissolved in glacial acetic acid (10 ml, 174.69 mmol) under N2. The 
reaction mixture was allowed to stir at room temperature overnight and then concentrated 
in vacuo. Ethyl acetate (2.5 ml) and diethyl ether (7.5 ml) were added to the mixture. Aq. 
NaOH (1 M) was also added until the PH of the aqueous layer was greater than 8. After 
that, the reaction mixture was cooled to 0 - 5 °C with an ice-water bath but only little 
solid formed. Ethyl acetate (20 ml) was used to extract the reaction and the aqueous layer 
was back-extracted with ethyl acetate (20 ml). Then the combined organic layers were 
washed with brine (30 ml), dried over anhydrous MgSO4, filtered and concentrated in 
vacuo. Much more solid formed when the product was left in the air overnight. Finally 
the product was washed with a solution of ethyl acetate and hexane to afford the title 
compound 91 as a white solid (269 mg, 46 %). Rf 0.4 (n-hexane/EtOAc 7:3); m.p. 180 - 
183 °C; νmax (ATR) 3209, 3142, 3062, 2935, 1708 (C=O), 1684 (C=O), 1608, 1578, 1533, 
1498, 1478, 1455, 1447, 1386, 1360, 1325, 1285, 1257, 1229, 1179, 1165, 1127, 1094, 
1081, 1066, 1021, 1002, 980, 942, 928 cm-1; δH (400 MHz, CDCl3) 8.60 (1H, s, CONH), 
7.09-7.56 (13H, m, Ar-H), 6.57 (1H, d, J 8, NH-Cbz), 5.33 (1H, d, J 8, NCHN), 5.17 (2H, 
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m, OCH2-Ar); δC (176 MHz, CDCl3) 168.0 (C=O), 166.6 (N-C-Ph), 155.7 (O-C=O), 
137.8 (ipso-Ar-C), 136.2 (ipso-Ar-C), 135.8 (ipso-Ar-C), 132.3 (Ar-C), 131.0 (Ar-C, 
ipso-Ar-C), 130.8 (Ar-C), 129.8 (Ar-C), 129.7 (Ar-C × 2), 128.6 (ipso-Ar-C), 128.5 (Ar-
C × 2), 128.4 (Ar-C × 2), 128.1 (Ar-C × 2), 122.8 (Ar-C), 69.0 (NCHN), 67.1 (OCH2-
Ar); m/z (ES+) 420 ([35Cl]MH+), 422 ([37Cl]MH+), 442 ([35Cl]MNa+), 444 ([37Cl]MNa+), 
861 ([35,35Cl]2M+Na+), 863 ([35,37Cl]2M+Na+), 865 ([37,37Cl]2M+Na+); HRMS (ES+) 
Found MH+, 420.1128 (C23H19
35ClN3O3 requires 420.1115). 
 
3-Amino-7-chloro-5-phenyl-1,3-dihydro-2H-benzo[e][1,4]diazepin-2-one 111 
 
 
 
Benzyl(7-chloro-2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl)carbamate 
91 (150 mg, 0.36 mmol) was dissolved in the hydrobromic acid solution (33 wt. % in 
acetic acid, 5 ml, 86.52 mmol). The reaction solution was stirred, refluxed at 70 °C and 
held for 20 min. Then the temperature was raised to 80 °C and maintained for another 20 
min. After refluxing, the resulting yellow slurry was cooled to ambient temperature, 
diluted with anhydrous diethyl ether (5 ml) and stirred for 30 min. Yellow solid was 
obtained by filtration. Then the resulting solid was washed with anhydrous diethyl ether 
and dried under vacuum to provide the dihydrobromide salt (124 mg, 0.28 mmol). The 
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aq. K2CO3 (5 % w/v, 10 ml) and ethyl acetate (10 ml) containing 2-propanol (0.5 ml) and 
dichloromethane (0.5 ml) were added to the dihydrobromide salt. Then the free base was 
isolated by removing the basic aqueous layer. The organic layer was dried over 
anhydrous MgSO4, filtered and concentrated in vacuo. The title compound 111 was 
obtained as a white solid (72 mg, 71 %). Rf 0.5 (DCM/MeOH 9:1); m.p. 197 - 200 °C; 
νmax (ATR) 3383, 3315, 3063, 3017, 2889, 2813, 2708, 1690 (C=O), 1603, 1591, 1575, 
1558, 1447, 1411, 1388, 1337, 1328, 1317, 1288, 1230, 1194, 1166, 1129, 1093, 1080, 
1014, 939, 930, 912 cm-1; δH (400 MHz, CDCl3) 8.26 (1H, s, CONH), 7.08-7.58 (8H, m, 
Ar-H), 4.50 (1H, s, NCHN), 2.50 (2H, bs, NH2); δC (176 MHz, CDCl3) 170.6 (C=O), 
165.4 (C-Ph), 138.1 (ipso-Ar-C), 136.2 (ipso-Ar-C), 132.1 (Ar-C), 130.8 (Ar-C), 130.4 
(C-Cl), 129.6 (Ar-C × 2), 129.3 (Ar-C), 129.0 (ipso-Ar-C), 128.4 (Ar-C × 2), 122.5 (Ar-
C), 70.3 (CHNH2); m/z (ES
+) 286 ([35Cl]MH+), 288 ([37Cl]MH+), 308 ([35Cl]MNa+), 310 
([37Cl]MMa+), 593 ([35,35Cl]2M+Na+), 595 ([35,37Cl]2M+Na+), 597 ([37,37Cl]2M+Na+); 
HRMS (ES+) Found MH+, 286.0753 (C15H13
35ClN3O requires 286.0747). 
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7-Chloro-3-((perfluoropyridin-4-yl)amino)-5-phenyl-1,3-dihydro-2H-
benzo[e][1,4]diazepin-2-one 116 
 
 
 
3-Amino-7-chloro-5-phenyl-1,3-dihydro-2H-benzo[e][1,4]diazepin-2-one 111 (45 mg, 
0.16 mmol) and pentafluoropyridine 46 (0.02 ml, 0.18 mmol) were dissolved in a solution 
of dichloromethane (3 ml) and methanol (1 ml). Triethylamine (0.03 ml, 0.22 mmol) was 
also added to the reaction which was stirred under N2 at room temperature. After stirring 
for one night, the reaction was still not complete and additional pentafluoropyridine 46 
(0.04 ml, 0.36 mmol) and triethylamine (0.06 ml, 0.43 mmol) were added to react over 
weekend. The resulting solution was diluted with dichloromethane (10 ml) and then 
washed twice with water (2 x 10 ml). The organic layer was dried over anhydrous MgSO4, 
filtered and concentrated in vacuo. The crude compound was obtained as a light yellow 
solid (111 mg). Flash chromatography (DCM, DCM/MeOH [95:5], [9:1]) afforded the 
title compound 116 as a light yellow solid (69 mg, 99 %). Rf 0.8 (DCM/MeOH 9:1); m.p. 
239 - 240 °C; νmax (ATR) 3312, 3133, 2961, 1705 (C=O), 1647, 1598, 1545, 1481, 1446, 
1411, 1390, 1325, 1290, 1276, 1260, 1221, 1186, 1167, 1130, 1083, 1017, 977, 942, 933 
cm-1; δH (400 MHz, CDCl3) 8.35 (1H, s, CONH), 7.16 -7.62 (8H, m, Ar-H), 6.64 (1H, d, 
J 8, NH-Py), 5.40 (1H, d, J 8, NCHN); ); δC (176 MHz, CDCl3) 167.1 (C=O), 166.8 (C-
Ph), 137.6 (Py-C-NH), 135.3 (ipso-Ar-C × 2), 132.8 (C-F × 2), 131.4 (C-F × 2), 130.8 
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(Ar-C × 2), 130.4 (C-Cl), 129.6 (Ar-C × 2), 128.7 (ipso-Ar-C), 128.6 (Ar-C × 2), 122.9 
(Ar-C × 2), 70.1 (NCHN); δF (376 MHz, CDCl3) -89.30 (1F, m, Py-F), -93.38 (1F, m, 
Py-F), -144.53 (1F, m, Py-F), -164.39 (1F, m, Py-F); m/z (ES+) 435 ([35Cl]MH+), 437 
([37Cl]MH+), 457 ([35Cl]MNa+), 459 ([37Cl]MNa+); HRMS (ES+) Found MH+, 435.0633 
(C20H12
35ClF4N4O requires 435.0636). 
 
Benzyl (5-(4-bromophenyl)-2-oxo-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl) 
carbamate 89 
 
 
 
Stage 1 
2-(Benzotriazol-1-yl)-N-(benzyloxycarbonyl)glycine 81 (0.50 g, 1.53 mmol) was 
dissolved in anhydrous THF (5 ml) under N2 when cooling to 0 - 5 °C with an ice-water 
bath. Oxalyl chloride (2 M in methyl chloride, 1.05 ml, 2.10 mmol) was added to the 
glycine solution followed by a drop of anhydrous DMF to start the reaction. After 
maintaining the reaction at 0 - 5 °C for 2 h, a solution of 2-amino-4’-bromobenzophenone 
88 (0.39 g, 1.40 mmol) and 4-methylmorpholine (0.46 ml, 4.20 mmol) in anhydrous THF 
(1.5 ml) was added dropwise to the reaction mixture by syringe. Then the ice-water bath 
was removed and the reaction was allowed to warm to room temperature. The reaction 
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slurry was filtered and the filter cake was washed with a small amount of anhydrous THF. 
After that, the mother liquor containing acyl amide was concentrated in vacuo. The crude 
acyl amide was used directly in the next step. 
 
Stage 2 
Ammonia solution (2 M in ethanol, 4.2 ml, 8.40 mmol) was added to the acyl amide from 
the last step under N2 to react over weekend. Then ethyl acetate (30 ml) was added to the 
reaction solution, which was later washed twice with aq. NaOH (1 M, 2 x 20 ml). The 
combined aqueous layers were back-extracted with ethyl acetate (20 ml). The organic 
layers were combined, washed twice with brine (2 x 20 ml). It was then dried over 
anhydrous MgSO4, filtered and concentrated in vacuo.  
 
The crude amine (1.23 g) was combined with ammonium acetate (0.50 g, 6.49 mmol) 
and they were dissolved in glacial acetic acid (10 ml, 174.69 mmol) under N2. The 
reaction mixture was allowed to stir at room temperature overnight and concentrated in 
vacuo. Ethyl acetate (2.5 ml) and diethyl ether (7.5 ml) were added to the mixture. Aq. 
NaOH (1 M) was also added until the PH of the aqueous layer was greater than 8. The 
reaction mixture was cooled to 0 - 5 °C with an ice-water bath but only little solid formed. 
Ethyl acetate (20 ml) was used to extract the reaction and the aqueous layer was back-
extracted with ethyl acetate (20 ml). Then the combined organic layers were washed with 
brine (30 ml), dried over anhydrous MgSO4, filtered and concentrated in vacuo. The 
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crude product was obtained as a brown gum (638 mg). Flash chromatography (n-hexane, 
n-hexane/EtOAc [9:1], [4:1], [7:3], [3:2], [1:1]) afforded the title compound 89 as a 
yellow solid (324 mg, 50 %). Rf 0.5 (n-hexane/EtOAc 7:3); m.p. 174 - 176 °C ; νmax 
(ATR) 3417, 3212, 3032, 2956, 1713 (C=O), 1689 (C=O), 1614, 1586, 1526, 1496, 1476, 
1446, 1389, 1358, 1324, 1292, 1254, 1230, 1194, 1179, 1162, 1121, 1083, 1060, 1026, 
1010, 975, 953, 937, 927, 911 cm-1; δH (400 MHz, CDCl3) 9.02 (1H, s, CONH), 7.14-
7.84 (13H, m, Ar-H), 6.62 (1H, d, J 8, NH-Cbz), 5.32 (1H, d, J 8, NCHN), 5.16 (2H, m, 
OCH2-Ar); δC (176 MHz, CDCl3) 168.3 (C=O), 166.8 (N-C-Ph), 155.8 (O-C=O), 137.3 
(ipso-Ar-C), 136.2 (ipso-Ar-C), 136.1 (ipso-Ar-C), 132.4 (Ar-C), 132.0 (Ar-C), 131.5 
(Ar-C × 2), 131.4 (Ar-C × 2), 131.1 (Ar-C), 128.5 (Ar-C × 2), 128.2 (Ar-C), 128.1 (Ar-
C × 2), 125.4 (ipso-Ar-C), 125.3 (ipso-Ar-C), 121.5 (Ar-C), 69.0 (NCHN), 67.1 (OCH2-
Ar); m/z (ES+) 464 ([79Br]MH+), 466 ([81Br]MH+), 486 ([79Br]MNa+), 488 ([81Br]MNa+), 
949 ([79,79Br]2M+Na+), 951 ([79,81Br]2M+Na+), 953 ([81,81Br]2M+Na+); HRMS (ES+) 
Found MH+, 464.0602 (C23H19
79BrN3O3 requires 464.0610).  
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5-(4-bromophenyl)-1-(perfluoropyridin-4-yl)-3-((perfluoropyridin-4-
yl)amino)-1,3-dihydro-2H-benzo[e][1,4]diazepin-2-one 118 
 
 
 
Stage 1 
Benzyl (5-(4-bromophenyl) - 2 - oxo - 2,3 - dihydro - 1H - benzo[e][1,4]diazepin - 3 - yl) 
carbamate 89 (100 mg, 0.22 mmol) was dissolved in the hydrobromic acid solution (33 
wt. % in acetic acid, 4 ml, 69.21 mmol). The reaction solution was stirred and refluxed 
at 70 °C for 20 min. Then the temperature was raised to 80 °C and maintained for another 
20 min. After refluxing, the resulting yellow slurry was cooled to ambient temperature, 
diluted with anhydrous diethyl ether (5 ml) and stirred for 30 min. The solvent was 
evaporated to provide the crude dihydrobromide salt as a brown gum (234 mg). The aq. 
K2CO3 (5 % w/v, 10 ml) and ethyl acetate (10 ml) containing 2-propanol (0.5 ml) and 
dichloromethane (0.5 ml) were added to the crude dihydrobromide salt. Then the free 
base was isolated by removing the basic aqueous layer. The organic layer was dried over 
anhydrous MgSO4, filtered and concentrated in vacuo. The crude 3-amino-5-(4-
bromophenyl)-1,3-dihydro-2H-benzo[e][1,4]diazepin-2-one was obtained as a brown 
gum (67 mg) and used directly in the next step. 
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Stage 2 
Pentafluoropyridine 46 (0.05 ml, 0.46 mmol) was added to the crude compound from the 
last stage and they were dissolved in dichloromethane (2 ml). Triethylamine (0.1 ml, 0.72 
mmol) was also added to the reaction solution which was later stirred under N2 at room 
temperature overnight. After that, the reaction solution was diluted with dichloromethane 
(10 ml) and washed twice with water (2 x 10 ml). The organic layer was dried over 
anhydrous MgSO4, filtered and concentrated in vacuo. The crude product was obtained 
as a brown gum (161 mg). Flash chromatography (n-hexane, n-hexane/EtOAc [9:1], [4:1], 
[7:3]) afforded the title compound 118 as an orange solid (37 mg, 35 %). Rf 0.7 (n-
hexane/EtOAc 7:3); m.p. 76 - 79 °C; νmax (ATR) 2955, 2924, 2854, 1721(C=O), 1641, 
1603, 1588, 1544, 1475, 1446, 1418, 1395, 1362, 1311, 1267, 1246, 1215, 1189, 1122, 
1097, 1070, 1054, 1011, 997, 966, 930 cm-1; δH (400 MHz, CDCl3) 7.07-7.67 (8H, m, 
Ar-H), 6.47 (1H, d, J 8, NH-Py), 5.72 (1H, d, J 8, NCHN); δC (176 MHz, CDCl3) 167.3 
(C=O), 164.9 (C-Ph), 141.8 (Py-C-N), 138.6 (Py-C-N), 137.5 (ipso-Ar-C), 136.1 (ipso-
Ar-C ), 133.2 (Ar-C × 2), 132.0 (C-F × 4), 130.9 (C-F × 4), 130.7 (Ar-C × 2), 127.3 (Ar-
C × 2), 126.5 (Ar-C), 123.1 (Ar-C, ipso-Ar-C), 116.3 (C-Br), 70.6 (NCHN); δF (376 MHz, 
CDCl3) -86.56 (1F, m, Py-F), -86.88 (1F, m, Py-F), -92.84 (2F, m, Py-F), -140.73 (1F, 
m, Py-F), -146.43 (1F, m, Py-F), -161.84 (2F, m, Py-F); m/z (ES+) 628 ([79Br]MH+), 630 
([81Br]MH+), 650 ([79Br]MNa+), 652 ([81Br]MNa+); HRMS (ES+) Found MH+, 628.0048 
(C25H11
79BrF8N5O requires 628.0019). 
 
97 
 
Benzyl (7-chloro-5-(2-fluorophenyl)-2-oxo-2,3-dihydro-1H-benzo[e][1,4] 
diazepin-3-yl)carbamate 94 
 
 
 
 
Stage 1 
2-(Benzotriazol-1-yl)-N-(benzyloxycarbonyl)glycine 81 (0.50 g, 1.53 mmol) was 
dissolved in anhydrous THF (5 ml) under N2 when cooling to 0 - 5 °C with an ice-water 
bath. Oxalyl chloride (2 M in methyl chloride, 1.05 ml, 2.10 mmol) was added to the 
glycine solution followed by a drop of anhydrous DMF to start the reaction. After 
maintaining the reaction at 0 - 5 °C for 2 h, a solution of 2-amino-5-chloro-2’-fluoro-
benzophenone 92 (0.35 g, 1.40 mmol) and 4-methylmorpholine (0.46 ml, 4.20 mmol) in 
anhydrous THF (1.5 ml) was added dropwise to the reaction mixture by syringe. Then 
the ice-water bath was removed and the reaction was allowed to warm to room 
temperature. The reaction slurry was filtered and the filter cake was washed with a small 
amount of anhydrous THF. After that, the mother liquor containing acyl amide was 
concentrated in vacuo. The crude acyl amide was used directly in the next step. 
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Stage 2 
Ammonia solution (2 M in ethanol, 4.2 ml, 8.40 mmol) was added to the acyl amide from 
the last step under N2 to react over weekend. Then ethyl acetate (30 ml) was added to the 
reaction solution, which was later washed twice with aq. NaOH (1 M, 2 x 20 ml). The 
combined aqueous layers were back-extracted with ethyl acetate (30 ml). The organic 
layers were combined, washed twice with brine (2 x 20 ml). It was then dried over 
anhydrous MgSO4, filtered and concentrated in vacuo.  
 
The crude amine (1.01 g) was combined with ammonium acetate (0.50 g, 6.49 mmol) 
and they were dissolved in glacial acetic acid (10 ml, 174.69 mmol) under N2. The 
reaction mixture was allowed to stir at room temperature overnight and concentrated in 
vacuo. Ethyl acetate (2.5 ml) and diethyl ether (7.5 ml) were added to the mixture. Aq. 
NaOH (1 M) was also added until the PH of the aqueous layer was greater than 8. Ethyl 
acetate (20 ml) was used to extract the reaction and the aqueous layer was back-extracted 
with ethyl acetate (20 ml). Then the combined organic layers were washed with brine (30 
ml), dried over anhydrous MgSO4, filtered and concentrated in vacuo. The crude product 
was obtained as a brown gum (742 mg). Flash chromatography (n-hexane, n-
hexane/EtOAc [9:1], [17:3], [4:1], [7:3]) afforded the title compound 94 as a yellow solid 
(301 mg, 49 %). Rf 0.3 (n-hexane/EtOAc 7:3); m.p. 166 - 169 °C; νmax (ATR) 3414, 3218, 
3148, 3063, 2925, 1712 (C=O), 1691 (C=O), 1613, 1576, 1501, 1482, 1464, 1452, 1399, 
1363, 1327, 1286, 1267, 1228, 1213, 1166, 1136, 1098, 1059, 1028, 1016, 1003, 991, 
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976, 945, 908 cm-1; δH (400 MHz, CDCl3) 8.64 (1H, m, CONH), 7.00-7.75 (12H, m, Ar-
H), 6.60 (1H, d, J 8, NH-Cbz), 5.34 (1H, d, J 8, NCHN), 5.17 (2H, m, OCH2-Ar); δC (176 
MHz, CDCl3) 167.5 (C=O), 163.5 (N-C-Ph), 161.1 (C-F), 155.7 (O-C=O), 136.1 (ipso-
Ar-C), 134.7 (ipso-Ar-C), 132.7 (Ar-C), 132.4 (Ar-C), 131.8 (C-Cl), 130.2 (Ar-C), 129.8 
(ipso-Ar-C), 129.3 (Ar-C), 128.7 (Ar-C), 128.5 (Ar-C × 2), 128.1 (Ar-C × 2), 124.6 (ipso-
Ar-C), 122.9 (Ar-C), 116.3 (Ar-C), 116.1 (Ar-C), 69.0 (NCHN), 67.1 (OCH2-Ar); δF (376 
MHz, CDCl3) -111.97 (1F, m, Ar-F); m/z (ES
+) 438 ([35Cl]MH+), 440 ([37Cl]MH+), 460 
([35Cl]MNa+), 462 ([37Cl]MNa+), 897 ([35,35Cl]2M+Na+), 899 ([35,37Cl]2M+Na+), 901 
([37,37Cl]2M+Na+); HRMS (ES+) Found MH+, 438.1018 (C23H18
35ClFN3O3 requires 
438.1021). 
 
7-chloro-5-(2-fluorophenyl)-3-((perfluoropyridin-4-yl)amino)-1,3-dihydro-
2H-benzo[e][1,4]diazepin-2-one 117 
 
 
 
Stage 1 
Benzyl (7-chloro-5-(2-fluorophenyl)-2-oxo-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl) 
carbamate 94 (200 mg, 0.46 mmol) was dissolved in the hydrobromic acid solution (33 
wt. % in acetic acid, 5 ml, 86.52 mmol). The reaction solution was stirred and refluxed 
at 70 °C for 20 min. Then the temperature was raised to 80 °C and maintained for another 
100 
 
20 min. After refluxing, the resulting yellow slurry was cooled to ambient temperature, 
diluted with anhydrous diethyl ether (5 ml) and stirred for 30 min. The solvent was 
evaporated to provide the brown acicular dihydrobromide salt (183 mg, 0.39 mmol). The 
aq. K2CO3 (5 % w/v, 10 ml) and ethyl acetate (10 ml) containing 2-propanol (0.5 ml) and 
dichloromethane (0.5 ml) were added to the dihydrobromide salt. Then the free base was 
isolated by removing the basic aqueous layer. The organic layer was dried over 
anhydrous MgSO4, filtered and concentrated in vacuo. The crude 3-amino-7-chloro-5-
(2-fluorophenyl)-1,3-dihydro-2H-benzo[e][1,4]diazepin-2-one was obtained as a light 
brown solid (89 mg) and used directly in the next step. 
 
Stage 2 
Pentafluoropyridine 46 (0.05 ml, 0.46 mmol) was added to the crude compound (75 mg) 
from the last stage and they were dissolved in dichloromethane (2 ml). Triethylamine 
(0.1 ml, 0.72 mmol) was also added to the reaction solution which was later stirred under 
N2 at room temperature overnight. After that, the reaction solution was diluted with 
dichloromethane (10 ml) and washed twice with water (2 x 10 ml). The organic layer 
was dried over anhydrous MgSO4, filtered and concentrated in vacuo. The crude product 
was obtained as a brown gum (110 mg). Flash chromatography (n-hexane, n-
hexane/EtOAc [9:1]) afforded the title compound 117 as yellow solid (54 mg, 31 %). Rf 
0.4 (n-hexane/EtOAc 7:3); m.p. 205 - 208 °C; νmax (ATR) 3373, 3200, 3076, 2929, 1689 
(C=O), 1647, 1610, 1539, 1478, 1452, 1413, 1394, 1376, 1324, 1268, 1219, 1188, 1169, 
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1133, 1083, 1021, 972, 946 cm-1; δH (400 MHz, CDCl3) 8.25 (1H, s, CONH), 7.04-7.73 
(7H, m, Ar-H), 6.69 (1H, d, J 8, NH-Py), 5.41 (1H, d, J 8, NCHN); δC (126 MHz, CDCl3) 
165.87 (C=O), 131.80 (Ar-C), 133.32 (Ar-C), 133.04 (Ar-C), 129.74 (Ar-C), 125.17 (Ar-
C), 123.36 (Ar-C), 116.54 (Ar-C), 70.26 (NCHN); δF (376 MHz, CDCl3) -93.26 (2F, s, 
Py-F), -112.32 (1F, s, Ar-F), -161.65 (2F, s, Py-F); m/z (ES+) 453 ([35Cl]MH+), 455 
([37Cl]MH+), 475 ([35Cl]MNa+), 477 ([37Cl]MNa; HRMS (ES+); Found MH+, 453.0545 
(C20H11
35ClF5N4O requires 453.0542). 
 
Benzyl (8-methyl-2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl) 
carbamate 95 
 
 
 
Stage 1 
2-(Benzotriazol-1-yl)-N-(benzyloxycarbonyl)glycine 81 (0.50 g, 1.53 mmol) was 
dissolved in anhydrous THF (5 ml) under N2 when cooling to 0 - 5 °C with an ice-water 
bath. Oxalyl chloride (2 M in methyl chloride, 1.05 ml, 2.10 mmol) was added to the 
glycine solution followed by a drop of anhydrous DMF to start the reaction. After 
maintaining the reaction at 0 - 5 °C for 2 h, a solution of 2-amino-4-methylbenzophenone 
93 (0.30 g, 1.40 mmol) and 4-methylmorpholine (0.46 ml, 4.20 mmol) in anhydrous THF 
(1.5 ml) was added dropwise to the reaction mixture by syringe. Then the ice-water bath 
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was removed and the reaction was allowed to warm to room temperature. The reaction 
slurry was filtered and the filter cake was washed with a small amount of anhydrous THF. 
After that, the mother liquor containing acyl amide was concentrated in vacuo. The crude 
acyl amide was used directly in the next step. 
 
Stage 2 
Ammonia solution (2 M in ethanol, 4.2 ml, 8.40 mmol) was added to the acyl amide from 
the last step under N2 to react over weekend. Then ethyl acetate (30 ml) was added to the 
reaction solution, which was later washed twice with aq. NaOH (1 M, 2 x 20 ml). The 
combined aqueous layers were back-extracted with ethyl acetate (20 ml). The organic 
layers were combined, washed twice with brine (2 x 20 ml). It was then dried over 
anhydrous MgSO4, filtered and concentrated in vacuo.  
 
The crude amine (0.67 g) was combined with ammonium acetate (0.50 g, 6.49 mmol) 
and they were dissolved in glacial acetic acid (10 ml, 174.69 mmol) under N2. The 
reaction mixture was allowed to stir at room temperature overnight and concentrated in 
vacuo. Ethyl acetate (2.5 ml) and diethyl ether (7.5 ml) were added to the mixture. Aq. 
NaOH (1 M) was also added until the PH of the aqueous layer was greater than 8. Ethyl 
acetate (30 ml) was used to extract the reaction and the aqueous layer was back-extracted 
with ethyl acetate (20 ml). Then the combined organic layers were washed with brine (30 
ml), dried over anhydrous MgSO4, filtered and concentrated in vacuo. The crude product 
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was obtained as a brown gum (403 mg). Flash chromatography (n-hexane, n-
hexane/EtOAc [9:1], [4:1]) afforded the title compound 95 as a yellow solid (246 mg, 
44 %). Rf 0.3 (n-hexane/EtOAc 7:3); δH (400 MHz, CDCl3) 8.49 (1H, s, CONH), 7.29-
7.64 (13H, m, Ar-H), 6.60 (1H, d, J 8, NH-Cbz), 5.33 (1H, d, J 8, NCHN), 5.16 (2H, s, 
OCH2-Ar), 2.43 (3H, s, CH3); m/z (ES
+) 400 (MH+), 422 (MNa+), 799 (2M+H+), 821 
(2M+Na+).  
 
Benzyl (3-oxo-6-phenyl-2,3,4,5-tetrahydropyrazin-2-yl)carbamate 105 
 
 
 
Stage 1 
2-(Benzotriazol-1-yl)-N-(benzyloxycarbonyl)glycine 81 (0.50 g, 1.53 mmol) was 
dissolved in anhydrous THF (5 ml) under N2 when cooling to 0 - 5 °C with an ice-water 
bath. Oxalyl chloride (2 M in methyl chloride, 1.05 ml, 2.10 mmol) was added to the 
glycine solution followed by a drop of anhydrous DMF to start the reaction. After 
maintaining the reaction at 0 - 5 °C for 2 h, a solution of 2-aminoacetophenone 104 
hydrochloride (0.24 g, 1.40 mmol) and 4-methylmorpholine (0.46 ml, 4.20 mmol) in 
anhydrous THF (1.5 ml) was added dropwise to the reaction mixture using pipptte. Then 
the ice-water bath was removed and the reaction was allowed to warm to room 
temperature overnight. The reaction slurry was filtered and the filter cake was washed 
104 
 
with a small amount of anhydrous THF. After that, the mother liquor containing acyl 
amide was concentrated in vacuo. The crude acyl amide was used directly in the next 
step. 
 
Stage 2 
Ammonia solution (2 M in ethanol, 4.2 ml, 8.40 mmol) was added to the acyl amide from 
the last step under N2 to react over weekend. Then ethyl acetate (30 ml) was added to the 
reaction solution, which was later washed twice with aq. NaOH (1 M, 2 x 20 ml). The 
combined aqueous layers were back-extracted with ethyl acetate (20 ml). The organic 
layers were combined, washed twice with brine (2 x 20 ml). It was then dried over 
anhydrous MgSO4, filtered and concentrated in vacuo.  
 
The crude amine (0.49 g) was obtained as a yellow solid and combined with ammonium 
acetate (0.50 g, 6.49 mmol) and they were dissolved in glacial acetic acid (10 ml, 174.69 
mmol) under N2. The reaction mixture was allowed to stir at room temperature overnight 
and concentrated in vacuo. Ethyl acetate (2.5 ml) and diethyl ether (7.5 ml) were added 
to the mixture. Aq. NaOH (1 M) was also added until the PH of the aqueous layer was 
greater than 8. Ethyl acetate (30 ml) was used to extract the reaction and the aqueous 
layer was back-extracted with ethyl acetate (30 ml). Then the combined organic layers 
were washed with brine (30 ml), dried over anhydrous MgSO4, filtered and concentrated 
in vacuo to afford the title compound 105 as an orange solid (298 mg, 66 %). Rf 0.4 
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(DCM/EtOH/NH3(aq.) 200:8:1); δH (400 MHz, CDCl3) 9.09 (1H, s, NH-Cbz), 8.41 (1H, 
s, CONH), 7.42-8.10 (10H, m, Ar-H), 6.26 (1H, s, NCHN), 5.29 (2H, s, OCH2-Ar), 4.12 
(2H, q, J 8, CH2NH); m/z (ES
+) 324 (MH+), 346 (MNa+). 
 
3-Amino-5-phenyl-3,6-dihydropyrazin-2(1H)-one 115 
 
 
 
Benzyl (3-oxo-6-phenyl-2,3,4,5-tetrahydropyrazin-2-yl)carbamate 105 (249mg, 0.77 
mmol)  was dissolved in the hydrobromic acid solution (33 wt. % in acetic acid, 5 ml, 
86.52 mmol). The reaction solution was stirred, refluxed at 70 °C and held for 20 min. 
Then the temperature was raised to 80 °C and maintained for additional 20 min. After 
refluxing, the resulting brown slurry was cooled to ambient temperature, diluted with 
anhydrous diethyl ether (5 ml) and stirred for 30 min. The solvent was evaporated and 
anhydrous diethyl ether (5 ml) was add to the mixture again. Then the dihydrobromide 
salt (260 mg, 0.74 mmol) was obtained by filtration. The aq. K2CO3 (5 % w/v, 10 ml) 
and ethyl acetate (10 ml) containing 2-propanol (0.5 ml) and dichloromethane (0.5 ml) 
were added to the dihydrobromide salt. The free base was isolated by removing the basic 
aqueous layer. The organic layer was wished with brine, dried over anhydrous MgSO4, 
filtered and concentrated in vacuo. The title compound 115 was obtained as an orange 
solid (67 mg, 46 %). Rf 0.4 (DCM/EtOH/NH3(aq.) 200:8:1); δH (400 MHz, CDCl3) 7.89 
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(1H, s, CONH), 7.29-7.54 (5H, m, Ar-H), 3.49 (2H, s, CH2NH), 2.17 (1H, s, NCHNH2); 
m/z (ES-) 188 (M-H-). 
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